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In the United States, coronary heart disease (CHD) is the most common cause of death and 
number one killer of American males and females. Several epidemiological studies have 
identified risk factors for CHD, like low high-density lipoprotein cholesterol (HDL-C), elevated 
total cholesterol and low-density lipoprotein (LDL) cholesterol, and high triglycerides (TGs), but 
underlying genetic variations that cause predisposition to these traits still remain unclear. 
Lipoprotein lipase (LPL) is one of the major genes involved in lipid metabolism and its gene 
sequence variation has already been reported to be associated with the risk of CHD and risk of 
other complex diseases like dyslipidemia, type 2 diabetes, essential hypertension, and 
Alzheimer’s disease. Unraveling the unknown genetic variation in the LPL gene in relation to 
HDL-C and correlated lipid traits is critically important for public health because identification 
of genetic markers may lead to promising future public health interventions, like prognostic tools 
and therapeutic approaches to alleviate the burden of CHD in the U.S. In this study, we 
investigated the role of common and rare variation in LPL by resequencing individuals having 
extremely low (n=48) and high (n=47) HDL-C levels selected from a population-based non-
Hispanic white (NHW) sample of 623 individuals. A total of 179 variants were identified in 95 
individuals by resequencing the entire LPL gene, including 91 uncommon or rare variants [minor 
allele frequency (MAF) <0.05)] and 88 common variants (MAF ≥0.05). Of the 91 relatively 
uncommon or rare variants, 21 were present only in the low-HDL group and 25 were present 
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only in the high HDL-C group. Overall, the prevalence of uncommon or rare variants was higher 
in the high HDL-C than the low HDL-C group. Thirty two of the 88 common variants 
demonstrated significant association (P-value <0.05) between the high and low HDL-C groups. 
We also examined 12 common variants (MAF ≥ 0.05) in the total NHW sample and identified 7 
variants to be significantly associated with lipid levels.  
In conclusion, our comprehensive resequencing of the LPL gene confirms that both 
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1.0    BACKGROUND AND SIGNIFICANCE 
1.1      CORONARY HEART DISEASE 
1.1.1    Public health importance of coronary heart disease 
In the United States, coronary heart disease (CHD) is the most common cause of death and major 
killer of American males and females; one of every six deaths is caused by CHD (Coronary Heart 
Disease) according to the National Vital Statistics in 2009 (Heron et al. 2009). Based on the 
Framingham Heart Study (FHS) in 2001 more than half of the total cardiovascular events were 
due to the CHD in females and males under age 75 (Lloyd-Jones et al. 2010; American Heart 
Association 2010). In  2006, almost 425,000 (224K males and 201K females) people died from 
CHD and the CHD death rate was 134.9 per 100,000 (176.3 for white males, 206.4 for black 
males, 101.5 for white females and 130.0 for black females (Lloyd-Jones et al. 2009). American 
Heart Association computation based latest available mortality data show that in every twenty 
five seconds an American will experience a coronary event and it will cause death of one person 
in about every minute. The same data computes that about 81% of Americans die of CHD are at 
age 65 or above (Lloyd-Jones et al. 2010). According to the data of National Health and Nutrition 
Examination Survey (NHANES) between 2003 and 2006, the prevalence of CHD in the United 
States was 17,600,000 for adults age 20 and older. It means 7.9 percent (9.1 percent for males and 
  2 
7.0 percent for females) of American adults age 20 and older have CHD (Lloyd-Jones et al. 
2010). The incidence is different between females and males; males at 40 and older have high risk 
of developing CHD than females at the same age. The percentages for lifetime risk of developing 
CHD are 48.6 % for males and 31.7% for women at age 40 (Ulrich et al. 1999). The latest 
available data of the American Heart Association estimates that the direct and indirect cost of 
CHD is $177.1 billion for 2009 (Lloyd-Jones et al. 2010). 
1.1.2    Risk factors of coronary heart disease 
The risk factors for CHD are classified into two categories according to their causative and 
quantitative contributions to CHD. Low level serum high-density lipoprotein (HDL) cholesterol, 
elevated serum total and low-density lipoprotein (LDL) cholesterol, elevated blood pressure, 
cigarette smoking, diabetes mellitus and advancing age are the major and independent risk 
factors. Several studies, including Framingham Heart Study, have investigated the quantitative 
relationship between these factors and CHD. The major and independent risk factors contribute 
the total risk of a person independently and total risk calculation can be done by summing of the 
risk imparted by each of the major risk factors. Second category includes predisposing and 
conditional risk factors that are associated with independent risk factors for CHD. Obesity, 
physical activity, ethnic characteristics, psychosocial factors, family history of premature CHD 
are predisposing risk factors  and elevated serum triglycerides, small LDL particles, elevated 
serum homocysteine, elevated serum lipoprotein (a), prothrombotic factors and inflammatory 
markers (eg. C-reactive protein) are conditional risk factors for CHD (Grundy et al. 1999). After 
nine years follow up, the data of the three prospective cohort studies includes both sexes and a 
spectrum of adult ages shows that 87% to 100% of fatal CHD cases had prior exposure to at least 
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one clinically elevated major CHD risk factor which are cholesterol ≥240 mg/dL [≥ 6.22mmol/L], 
arterial blood pressure ≥140/190 mm Hg, medication use for cholesterol and hypertension, high 
cholesterol, cigarette smoking or clinical diabetes; 64% to 100% of these fatal CHD cases had 
prior exposure to two or more major CHD risk factors at higher than favorable levels (Greenland 
et al. 2003). The mortality data, prevalence and incidence of CHD show that male gender and 
blacks has higher risk of developing a CHD (Keil et al. 1989; Cooper et al. 1992; Johnson et al. 
1986).  
Since family history is an important risk factor for CHD, several studies imply the 
importance of genetic factors in the pathogenesis of CHD due to their aggregation in families with 
combination of lifestyle and common environment (Jannotti et al. 2000; Tiret et al. 2002; Breslow 
et al. 2001). The heritability of these risk factors has been investigated in many twin studies to 
understand the role of shared genes and shared environment. These results strength the 
importance of the genetic factors in predisposition to CHD (Hans et al. 1997; Marenberg et al. 
1994; Chen et al. 2009; Austin et al. 1987). Most of the known genetic variation that affects the 
risk of CHD underlay in the genes that have an important role in lipid metabolism, including the 
lipoprotein lipase (LPL) gene. These variations may result a change in the gene function and 
cause changes in the lipid levels. This emphasizes the significance of the genetic studies for 
unraveling the genetic variation in candidate genes that may affect the lipid levels and contribute 
to the etiology of CHD.                                                          
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1.2    HIGH DENSITY LIPOPROTEIN (HDL) 
High density lipoprotein (HDL) is the smallest and densest lipoprotein particle in the circulation 
which consists of several distinct subclasses that vary in size, shape, density (1.063 to 1.21g/ml), 
surface charge and composition (Rye et al. 2009; Tsompanidi et al. 2009). The other major groups 
of lipoproteins, in order of largest to smallest according to their lipid content, are chylomicrons, 
very low density lipoprotein (VLDL), intermediate-density low protein (IDL), and low density 
lipoprotein (LDL). They are responsible to carry the lipids like cholesterol and triglyceride (TG) 
in the circulation. HDL particles compose by a hydrophobic core of cholesterol esters and a small 
amount of triglycerides (TGs); is surrounded by phospholipids, free cholesterol and 
apolipoproteins (apos) (Rye et al. 2009; Florentin et al. 2008). HDL may have a discodial or 
spherical shape depending on the lipid composition. Mature HDL is in spherical shape and 
contains 45-55% apolipoproteins, 26-32% phospholipids, 15-20% esterified cholesterol, 3-5% 
free cholesterol and about 5% triglycerides (Tsompanidi et al. 2009). The major apolipoprotein 
particles of HDL are apoAI and apoAII and the minor apolipoproteins are apoIV, apoCI/CII/CIII, 
apoD, apoE, apoJ, apoK and apoM (Florentin et al. 2008). HDL particles also include liposoluble, 
antioxidants, and several enzymes like paraoxonase-I (PONI), platelet-activating factor 
acetylhydrolase (PAF-AH) and glutathione phospholipid peroxidase (Florentine et al. 2008). As a 
major component of HDL, apoAI has a role in biogenesis and functions of HDL (Tsompanidi et 
al. 2009). 
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Although, high blood cholesterol is a major risk factor for CHD, cholesterol which is 
carried in HDL particles is called ‘good’ cholesterol and it is beneficial for a number of reasons 
(Toth, 2005; Genest et al. 1999). American Heart Association considers low high density 
lipoprotein (HDL-C) as a major risk factor for heart disease if it is less than 40 mg/dL for men 
and less than 50 mg/dL for women; HDL-C levels of 60 mg/dL and above is considered as  being 
protective against heart disease.  
1.2.1    HDL-Metabolism  
Unlike the other lipoprotein particles, HDL promotes the reverse cholesterol transport (RCT), 
carries the excess cholesterol from non-hepatic cells (such as macrophages) to the liver and 
steroidogenic organs so cholesterol can be able to use for the synthesis of lipoproteins, bile acids, 
Vitamin D, and steroid hormones (Genest et al. 1999; Stein et al.1999; Von Eckardstein et al 
2001). There are three different pathways that reverse cholesterol transport can take place. First, 
LDL receptors on liver recognize the multiple copies of apoE particles on mature HDL particles 
so they can be taken up by liver (Bruce et al. 1998). Second, scavenger receptor class B1 (SR-B1) 
mediates the selective uptake of the high-density lipoprotein cholesteryl esters (HDL-CE) (Acton 
et al. 1996). Third, cholesteryl ester transfer protein (CETP) transfers the cholesteryl esters from 
HDL to the TG rich lipoprotein particles, and then they can be taken by the liver via LDL 
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1.2.2    The antiatherogenic role of HDL particles 
The antiatherogenic role of HDL particles is mainly related its function in reverse cholesterol 
transport pathway which removes cholesterol from peripheral cells (macrophages in the artery 
wall) (Rye et al. 2009; Florentin et al. 2008). Besides this function, HDL has anti-thrombotic and 
anti-inflammatory properties that contribute to its atheroprotective role (Von Eckardstein et al. 
2001; Genest et al. 1991). It also prevents atherosclerotic lesion progression by inhibiting LDL 
oxidation, promoting endothelial repair, inhibiting the binding of monocytes to the endothelium 
and improving endothelial function (Rye et al. 2009; Assmann et al. 1993; Rust et al.1999) 
1.2.3    HDL cholesterol and CHD risk 
Lipid levels and their role in development of CHD have been studied since the early 1950s (Barr 
et al. 1951). Despite the fact that HDLs carry about 20% of the total plasma cholesterol, several 
clinical and epidemiological studies have demonstrated the inverse relationship between HDL-C 
and CHD (Gordon et al. 1989, Castelli et al. 1986, Castelli 1977). This was reported as a 1 mg/dL 
increase of HDL-C levels is associated with a 2-3% decreased CHD risk (Gordon et al. 1989). It 
is worth noting that although the direct relationship between the CHD risk and low HDL-C is 
clearly identified in many studies, this does not reflect a causal relationship due to other factors 
that affect CHD risk as well as HDL-C levels (Vergeer et al. 2010). The risk factors for CHD that 
also cause low level of HDL-C are: male gender, smoking, obesity, hypertriglyceridemia, insulin 
resistance, physical inactivity, systemic inflammation, and low socioeconomic status (Vergeer et 
al. 2010). 
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1.2.4    Effects of genetic factors on HDL-C levels 
Since the inverse relationship between HDL-C levels and CHD have been confirmed in various 
epidemiological studies, interest has focused on the role of genetic factors influencing HDL-C 
concentration (Weissglas-Volkov et al. 2010). Based on family and twin studies, the heritability 
of HDL-C levels is estimated up to 80 % (Kronenberg et al. 2002; Perusse et al., 1997; Wang and 
Paigen 2005; Goode et al. 2007). This means, in addition to environmental factors, genetic factors 
play an important role in affecting the variation of plasma HDL-C levels.  
The genetic inheritance of low and high HDL-C levels can be monogenic, polygenic, or 
can be determined by interactions between several genes and their interactions with 
environmental factors. Most of the researchers conduct studies by using case/controls, families, 
and unascertained populations to understand the role of major genes in lipid metabolism 
influencing HDL-C variations (Weissglas-Volkov et al. 2010). In this aspect, the mutations in the 
APOA1, ABCA1, LCAT, and LPL genes have been associated with low HDL-C levels and they 
cause monogenic disorders as apoAI deficiency, Tangier disease, familial lecithin-cholesterol-
acyl transferase (LCAT) deficiency (FLD), and lipoprotein lipase (LPL) deficiency (Type I 
hyperlipoproteinemia or familial chylomicronemia), respectively. However, mutations in the 
CETP and HL genes have been associated with high HDL-C levels (Weissglas-Volkov et al. 
2010). 
The approaches to identify the susceptibility genes in complex polygenic diseases fall into 
two categories: candidate gene studies and genome wide association studies (GWAS). The 
candidate gene studies using resequencing and association techniques have identified several 
variants in some of the genes that have a known important function in HDL metabolism. Among 
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these genes (CETP, LIPC, LPL, LIPG, LCAT, ABCA1, APOA1, APOC3, APOC5, APOE, SR-BI, 
and PON1), the common variants that have been identified in LPL, CETP, and LIPC are the most 
significantly associated with HDL-C levels (Weissglas-Volkov et al. 2010, Sviridov  et al.  2007).  
There are ten GWASs published on HDL-C levels (Willer et al. 2008, Kathiresan et al. 
2008a, Kooner et al.2008; Wallace et al. 2008; Kathiresan et al. 2007; Aulchenko et al., 2009, 
Chasman et al., 2008; Sabatti et al. 2009; Ridker et al. 2009, Heid et al. 2008). These results are 
consistent with the previous association studies and the strongest association signals were 
observed for SNPs in the LPL, CETP, and LIPC genes. However, these GWASs also identified 
new candidate genes influencing HDL-C levels which need further studies to understand their 
functional importance in the HDL metabolism.   
1.3    LIPOPROTEIN LIPASE 
The lipoprotein lipase (LPL protein; LPL gene) is located on chromosome 8p22 in humans 
(Sparkes et al. 1987). The National Center for Biotechnology Information (NCBI) reference 
nucleotide sequence is NC_00008.10 (http://www.ncbi.nlm.gov/sites/entrez). It is a member of 
the TG lipase gene family; the other genes in the same family are hepatic lipase (HL), pancreatic 
lipase (PL), and endothelial lipase (EL). The LPL gene comprises 10 exons spanning 30 kb (Deeb 
and Peng 1989). The gene encodes 475 amino acids and it becomes a mature protein of 448 
residues after cleavage of a 27-amino-acid signal peptide (Wion et al 1987). 5’- untranslated 
region, the signal peptide and the first two amino acids are encoded by the first exons. The rest of 
the 9 exons encode the remaining 446 amino acids. The 10th exon is the largest exon which 
encodes the long 3’-untranslated region of 1,948 nucleotides. Figure 1 shows the gene structure 
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and the basic promoter elements of the LPL gene which are located within 101bp upstream of the 
transcription starting site (Wang et al 2009). 
 
Figure 1. Lipoprotein lipase gene structure with promoter elements. (From Wang et al 2009, "Am Physiol 
Soc, used with permission") 
1.3.1    LPL gene regulation  
The expression and regulation of LPL is regulated at transcriptional, posttranscriptional, 
translational and posttranslational levels in a tissue specific manner. Hormonal levels and 
nutritional regulations can also affect the expression of LPL by interacting proteins or directly 
modify the regulation of LPL (Wang et al.  2009). Variations in LPL gene sequence, expression 
and regulation are important because they may influence its activity and also its contribution to 
disease so screening the LPL gene in people who have different level of HDL-C levels may 
explain how LPL variants affect HDL-C levels and CHD. HDL-C levels may be regulated in three 
different ways due to plasma LPL activity (Weissglas-Volkov 2010). First, some of the 
phospholipids and apolipoproteins are shed and transferred to the HDL particles during the 
hydrolysis of TG-rich lipoproteins (Klos et al. 2007). Second, LPL limits the CETP-mediated 
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HDL-C reduction by decreasing plasma TG because the exchange of cholesterol for TG from 
HDL is modulated by CETP due to the amount of VLDL particles (Rye et al. 2009). Third, HDL 
lipid composition is altered by LPL enzyme activity because affects the catabolic rate of apoA1 so 
they can be more rapidly cleared from the circulation (Barter et al. 2003).  
1.4   LIPOPROTEIN LIPASE ENZYME 
In 1943, Paul Hahn first observed clearance of postprandial lipidemic plasma heparin injection 
(Hahn 1943). After this finding, more studies focused on understanding the mechanism of so 
called heparin releasable ‘clearing factor’ and it was revealed that this factor is a lipolytic enzyme 
which has high activity against the TG component of plasma lipoproteins. The enzyme was called 
LPL, after discovering its role on breaking down plasma triglycerides of TG-rich lipoproteins 
which are VLDL and chylomicrons (Tsutsumi 2003). LPL is a major rate-limiting enzyme 
responsible for the hydrolysis of TG-rich particles circulating in the bloodstream, so it has a 
central role in overall lipid metabolism and transport.  ApoCII is required for activation of LPL 
and there are several factors such as apoCIII, apoE, high salt conditions and fatty acids that inhibit 
LPL activity (Murthy et al. 1996).  It is synthesized by parenchymal cells and then transferred to 
the luminal surface of endothelial cells where it is anchored to the surface of the cells by heparan 
sulfate proteoglycans (Goldberg et al. 1996).   
LPL enzyme activity has been detected in several extrahepatic tissues and cells, including 
adipose tissues which it is predominantly found and in other tissues such as heart, skeletal muscle, 
lung, lactating mammary gland, brain, kidney, and macrophages (Kirchgessner et al. 1989). LPL 
enzyme activity has been also identified in differentiated macrophages, placenta, spleen, 
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pancreatic β-cells and steroidgenic tissue, but not in liver of adult animals. Due to tissue-specific 
activity of LPL, high levels of hepatic messenger RNA and enzyme activities are shown during 
suckling period in lactating mammary glands (Semenkovich et al. 1989, Yacoub et al. 1952; 
Merkel et al. 1998a). The high level LPL activity in adipose tissue is seen after a meal consistent 
with the fat storage function of adipose tissue and its level is increased by fasting and exercise 
training in skeletal muscle (Merkel et al. 2002). 
The LPL enzyme is catalytically active in its dimer nascent form which is composed of 55 
kDa subunits and it shows a head-to-toe configuration by noncovalent interactions (Zhang et al. 
2005). Maturation of nascent LPL starts in the endoplasmic reticulum depending the activity of 
lipase maturation factor 1 (Peterfly et al. 2007). According to the three-dimensional structure of 
LPL, it has been shown that LPL is organized into two structurally distinct domains; a larger N-
terminal domain (residues 1-312) and a smaller C-terminal domain (residues 312-448) connected 
by a flexible peptide (Yang et al. 1989, Bengtsson-Olivecrone et al. 1986, Lookene et al. 1993) N-
terminal domain includes catalytic site covered by a lipid-binding lid and catalytic center consists 
of three amino acids: Ser132, Asp156, and His241. Interaction of LPL with lipoprotein substrates 
occurs in the C-domain and it results a conformational change that allows enzyme to conduct its 
catalytic function by opening of the lid in the N-terminal domain (Santamarina-Fojo et al. 1994). 
There are four distinct physiological activities of LPL that have been identified in several 
studies which all influence the plasma lipoprotein profile and the cellular metabolism of fatty 
acids and lipids (Preiss-Landl et al 2002). First and major activity of LPL is its hydrolyzing 
function of TG-rich lipoproteins (chylomicron and VLDL) to provide fatty acids to underlying 
tissues (Figure 2). Second, LPL has uncatalytic activity called ‘bridging function’ which allow 
enzyme to interact with lipoproteins and anchoring them to the vessel wall so it facilitate 
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triglyceride hydrolysis and lipoprotein uptake ( Merkel et al.1998b, Merkel et al. 2002). Third, 
LPL has a role in the uptake of lipoproteins by acting as a ligand for the LDL receptors, VLDL 
receptors, megalin, and LDL receptor related protein (Medh et al. 1996, Takahashi et al. 1995, 
Kounnas et al. 1993, Beisiegel et al. 1991). Fourth, LPL facilitates the selective uptake of 
lipoproteins associated lipids (Merkel et al. 2002; Seo et al. 2000) and lipophilic vitamins such as 
vitamin A and vitamin E (Preiss-Landl et al. 2002; Sattler et al. 1996; Van Bennekum et al. 1999).  
 
Figure 2. LPL activity in fatty acid transport to muscle and adipose tissues (Attie et al. 2010, used with 
permission). 
1.4.1    Effects of Lipoprotein Lipase activity on lipid levels  
Lipoprotein lipase is the major enzyme in lipid metabolism so its catalytic function and bridging 
function are both critically important for humans to maintain the lipid levels favorably. Due to its 
essential role in regulation of lipid metabolism, it is a candidate susceptibility gene for influencing 
CHD risk. Several studies show variations in the human LPL gene that have a role in the disease’s 
etiology due to changes in LPL gene sequence, expression and regulation (Xie et al. 2010). Havel 
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and Gordon discovered LPL deficiency in 1960 and then the gene was cloned in 1991 followed 
by identification of several mutations (Havel et al. 1960, Henderson et al. 1991). Clinically 
abnormal lipid levels have been associated with CHD, atherosclerosis and obesity in individuals 
who have a number of functional DNA sequence variations in their LPL gene (Murthy et al. 1996; 
Reymer et al. 1995; Brunzell et al. 1995; Wiebusch et al. 1992). LPL deficiency, known as  Type 
1 hyperlipoproteinemia or familial chylomicronemia (MIM 238600), is a rare autosomal recessive 
disorder (1/1,000,000) caused by defects in the LPL gene and it is correlated with severe 
hypertriglyceridemia due to chylomicronemia and VLDL accumulation with very low levels of 
LDL-C and HDL-C levels (<20mg/dL). LPL deficiency is characterized with 
hepatosplenomegaly, xanthomas, acute pancreatitis and recurrent episodes of abdominal pain 
(Klos et al. 2007). Several studies have shown that individuals with LPL deficiency are 
compound heterozygotes and most of the disease causing mutations occur predominantly in exons 
4, 5 and 6 of the LPL gene. The disease causing mutations usually result catalytically inactive 
LPL enzyme that is being degraded within the cell and cause little or no postheparin LPL activity 
(Wang et al. 2009).  
1.5   LIPOPROTEIN LIPASE GENE SEQUENCE VARIATION 
LPL is a candidate gene for influencing the risk of CHD due to its central role in lipid 
metabolism. Hypertriglyceridemia, which is the main clinical feature of LPL deficiency and 
dysfunction may be also a risk factor in the pathogenesis of CHD as well as dsylipidemia, type 2 
diabetes (T2D), essential hypertension (EH), and Alzheimer’s disease (Xie et al. 2010). It is 
thought to be a common biological basis for these complex diseases that structure, expression and 
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function of the LPL gene may have a role in that. This explains importance of understanding the 
LPL gene sequence variation and its association between specific phenotypes. Initially, 9.7kb of 
LPL sequence, about one-third of the LPL gene, was sequenced in 71 individuals, that identified 
88 variable sites (79 were single nucleotide substitutions and 9 were insertion-deletion) 
(Nickerson et al. 1998). The average nucleotide diversity across the region, spanning from 3’ end 
of intron 3 to the 5’ end of intron 9, was found to be 0.2 %, which is almost one variant in every 
500bp (Nickerson et al. 1998). Nickerson et al. (1998) sequenced a total of 9,734bp including 
8,736bp in non-coding region and 9,98bp in coding region; 81 variants were identified in non-
coding region and 7 variants were identified in coding region. Most of the variable sites detected 
in the coding region were silent and third base substitutions except one variable site that leads to 
stop codon and premature truncation of the protein in position 9040C>G (447Ser→Ter) and three 
amino-acid substitutions were observed in the coding region in positions 2849A>G 
(291Asn→Ser), 6176 G>A (370Val→Met), and 6203A>G (379Thr→Ala) (Nickerson et al. 
1998). In another study, sequence variants were identified by resequencing all 10 exons and 
introns/flanking regions of the human LPL gene in 95 subjects, and 24 variants were identified 
including 9 in coding and 15 in non-coding regions (Morabia et al. 2002). Three of the 24 variants 
were found to be associated with amino acid changes; 291Asn291→Ser (N291S) in exon 6 and 
447Ser→Ter (S447X) in exon 9 and 9Asp→Asn (D9N) in exon 2 (Morabia et al. 2002). In 
addition to these common coding variants,  almost 100 naturally occurring mutation have been 
described in LPL gene: 61 missense mutation, 12 nonsense mutations, 10 frameshift mutations or 
small insertion/deletions, 3 gross mutations, 8 splicing mutations and 4 promoter variants (Merkel 
et al. 2002). Ser447X is the only variant associated with increased LPL activity and found in up to 
20% in the general population (Merkel et al. 2002). The most common LPL coding variants with 
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their locations and percentages of carriers in related populations are briefly described in the Table 
1. 
 
Table 1. Most common LPL variants 
1.6   LPL POLYMORPHISMS ASSOCIATED WITH PLASMA HDL-C LEVELS AND 
CORONARY HEART DISEASE 
Several studies have investigated the association of LPL polymorphisms with HDL-C levels 
(Boes et al. 2009). Seven variants have showen significant association with HDL-C levels. Two 
of them are the common variants (Asp9Asn, N291S) that result amino acid changes and lead to 
decrease in enzymatic activity and so they have been projected to reduce HDL-C levels (Wittrup 
et al. 1999, Zhang et al. 1996; Mailly et al. 1995). While D9N (rs1801177) results in 3.2 mg/dl 
decrease in HDL-C levels and 20% increase in TG levels, Asn291Ser (rs268) leads to 4.6mg/dl 
decrease in HDL-C levels (Wittrup et al. 1999). The D9N variant is in near-complete linkage 
disequilibrium with the promoter variant (T93G), which may cause decreased LPL activity due to 
lower promoter activity but the role of the promoter variant is not yet clear (Merkel et al. 2002). 
The other amino acid substitution, Gly188Glu, decreases HDL-C levels (10mg/dl) and it is most 
LPL Variant Location Carrier frequencies (%) in populations 
Ser447X Exon 9 20% in Caucasians (Humphries et al. 1998, Wittrup et al. 1999) 
Asp9Asn Exon 2 1.5% in Caucasians (Wittrup et al. 1999) 
Asn291Ser Exon 6 2-5% in Caucasians (Wittekoek et al. 1998) 
-93T→G Promotor 76.4% in South African Blacks and 1.7% in Caucasians (Ehrenborg et al. 1997) 
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frequent in French Canadians in Quebec (Wittrup et al. 1999; Merkel et al. 2002). It is the major 
mutation that results nonfunctional LPL protein and has the strongest link with increased risk of 
CHD among all LPL variants (Merkel et al. 2002). The HindIII (rs320) polymorphism is located 
in intron 8 of the LPL gene and is in strong linkage disequilibrium with the Ser447X variant 
(Humphries et al. 1998). The HindIII polymorphism has been estimated to increase HDL-C levels 
up to 5.5mg/dl (Senti et al. 2001; Holmer et al. 2000; Corella et al. 2002; Ukkola et al. 2001; 
Radha et al. 2006, Ahn et al. 1993). Ser447X (rs328) is the other common variant that cause stop 
codon and it is also associated with increased HDL-C levels in several studies (Wittrup et al. 
1999; Nettleton et al. 2007; Lee et al. 2004; Komurcu-Bayrak et al. 2007; Pallaud et al. 2001; 
Constanza et al. 2005; Kathiresan et al. 2008b; Talmud et al. 2002). Two single nucleotide 
polymorphisms (SNPs), rs326 and rs13702, have been identified to be in a strong LD with rs320 
so they are also associated with HDL-C levels (Boes et al. 2009; Klos et al. 2006). 
Genome wide association (GWA) studies have also identified many SNPs associated with 
HDL-C levels. To our knowledge, seven GWA studies have found association signals in the LPL 
gene with HDL-C levels (Boes et al. 2010). The reported SNPs with the lowest p-values are 
rs2083637 (Aulchenko et al. 2009), rs10503669 (Willer et al. 2008), rs331 (Chasman et al. 2008), 
rs328 (Kathiresan et al. 2008b), rs17482753 (Heid et al. 2008), rs17411031 (Wallacee et al. 
2008), and rs326 (Kooner et al. 2008). 
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1.7   SPECIFIC AIMS 
The objective of this study is to evaluate the role of common and rare genetic variation in the LPL 
gene in relation to HDL-C and correlated lipid traits in a non-Hispanic white (NHW) sample 
(n=623). Since LPL is a biological candidate gene for HDL-C levels, its common and/or rare 
variation is hypothesized to contribute to the variation in HDL-C levels. The following are the 
three aims of our study. 
Aim 1: Resequence the LPL gene in a subset of phenotypically determined samples having 
HDL-C in the upper (n=47) and lower (n=48) 5th percentile derived from a NHW sample of 623 
individuals to identify both rare (allele frequency <0.01) and common variants (allele frequency 
≥0.05).  
Aim 2: Screen the tagSNPs of common variants of the LPL gene in the total NHW sample 
(n=623). 
           Aim 3: Evaluate the association of both rare and common LPL variants identified in Aim 1 
and Aim 2 with HDL-C and correlated lipids (total cholesterol, triglycerides, LDL-C) levels in the 
NHW sample. 
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2.0   SUBJECTS AND METHODS 
2.1   SUBJECTS 
The study samples comprised 623 non-Hispanic whites (NHWs) derived from the San Luis 
Valley Diabetes Study in Colorado. The main features of the study subjects are depicted in Table 
2. All subjects used in this current study were non-diabetics and a more detailed description of the 
sample population is given in Razagghi et al. (2000) and Demirci et al. (2010). Total fasting 
serum cholesterol was determined by using esterase-oxidase method, total HDL-C and TG were 
measured using enzymatic methods and LDL-C was calculated by the Friedewald equation when 
triglycerides levels were less than 400mg/dl (4.5 mmol/l) (Harris et al. 1998).  
DNA was extracted from buffy coat using standard DNA extraction procedures. 
                 Table 2. Population characteristic data (mean±SD) of entire NHW (n=623) 
Variable Men (n=295) Women (n=328) 
      Age (years) 52.9 ± 0.6  52.4 ± 0.6  
      BMI (kg/m2) 26.2 ± 0.20  24.8 ± 0.2  
      LDL (mg/dl) 139.8± 2.0  134.7± 2.0  
      HDL-C (mg/dl) 43.9 ± 0.6  56.3 ± 0.7  
     Triglycerides (mg/dl) 147.6 ± 4.1  128.2 ± 2.9  
Total Cholesterol  (mg/dl) 213.7 ± 2.2  217.7 ± 2.1  
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A total of 95 NHW individuals whose serum HDL-C in the upper 5th (n=47) and in the lower 5th 
(n=48) percentiles were selected for resequencing of the entire LPL gene. Of the selected 95 
individuals, 47 were females (23 with high HDL-C levels and 24 with low HDL-C levels) and 48 
were (24 with high HDL-C levels and 24 with low HDL-C levels) males. A summary of the 
selected sample of 95 individuals is presented in Table 3. 
 
Table 3. Population characteristic data (mean±SD) of the subset of population used for DNA sequencing 
 
Variable 
Total n=95  
p-value High   HDL(n=47) Low HDL(n=48) 
Age (years) 55.45 ± 9.8 53.03 ± 10.54 0.25 
Sex (M/F) 24/23 24/24 0.92 
BMI (kg/m2) 23.17 ± 3.17 27.35 ± 3.90 <0.001 
LDL (mg/dl) 126.84 ± 46.95 136.95 ± 41.28 0.28 
HDL-C (mg/dl) 77.68 ± 13.32 31.81 ± 4.37 <0.001 
Triglycerides (mg/dl) 114.09 ± 60.88 240.21±153.22 <0.001 
Total Cholesterol (mg/dl) 227.34 ± 51.76 208.81 ± 44.65 0.06 
2.2   DNA SEQUENCING 
The LPL gene is located on chromosome 8p22 and comprises 10 exons. Figure 3 depicts the 
location of the LPL gene on chromosome 8 with neighboring genes and indicates their 
orientations. The accession number for DNA reference sequence for LPL gene used in PCR and 
resequencing is NC_00008.10; it is derived from Genbank in NCBI site 
(http://www.ncbi.nlm.nih.gov). A total of 37 overlapping resequencing amplicons were 
sequenced in both directions and the PCR primers that were used to produce these overlapping 
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amplicons are given in Table 4. These amplicons cover the entire LPL gene (27,993 bp) as well as 
1,196 bp in the 5’ flanking region and 1kb in the 3’flanking region resulting into a total of 30,189 
bp genomic fragment. Although we design most of the primers by using Pimer 3 software 
(http://frodo.wi.mit.edu/primer3/), we also used a subset of primers from a previous study 
(Nickerson et al. 1998). That sequenced only a portion of the targeted region (9.7kb), starting 3’ 
end of intron 3 to 5’ end of intron 9.  
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Forward Primer Reverse Primer Internal Sequencing  Primer 
1 822 5'-GGGTTGGGGATACACTTCAT-3' 5'-TGTTTTCCAAGGAGGGAAAG-3'  
2 722 5'-TGATCCATCTTGCCAATGTT-3' 5'-AGGGCTTTGCTCTCCATCT-3'  
3 851 5'-GAAAGCTGCCCACTTCTAGC-3' 5'-GTACTTTCTCCACCCCGACA-3'  
4 703 5'-TGACCTGCAGTCACCTCTCT-3' 5'-GCTCTCTATGCTGCTGTTGC-3'  
5 800 5'-GGGGCCAAATGAGAATGTC-3' 5'-AGTTGGCTCCTACCATCTTC-3'  
6 1177 5'-GGATCAGTTTGAAAACACTGGA -3' 5'-CATTTTGATGGCTGGAACAT-3'  
7 1112 5'-TGCCTTATGCCAGATTGTTC-3' 5'-TTGAATGAAGGGCTGTTGAG-3'  
8 1147 5'-ATACCATTCTGGCTTGGATT-3' 5'-ACTGATGTGGTCGATTTGGT-3'  
9 1056 5'-AGCTGCATGTTAGAGAAGTCAA-3' 5'-CCAAACTTCAGTCAGCTCTCC-3'  
10 1093 5'-CTGCCCAATAGCAATCACAG-3' 5'-CAATGGGTAAACACTCCAAGA-3'  
11 1113 5'-TCTTGGTGGATGAATGGAT-3' 5'-ATTACCAGTGTGAGCCATCG-3'  
12 1022 5'-GCCATAGGAGTGGGAACAGT -3' 5'-ACTGGAGGGTTGCTTGATTT-3'  
13 787 5'-TCGAAAACACTTCAGAAACAAAA-3' 5'-AGTAAATGGAGGCCCAGAGA-3'  
14 1090 5'-CTGCGAGGTTGGTAAAGGAT-3' 5'-CCTGCCTGTGCTGAAAATA-3'  
15 1053 5'-TGTGATAAAATCTCAAATTCCTAAA-3' 5'-TCCTACAGTGGCTGACATTTTT-3'  
16 1019 5'-AGGGAGGGCTTCAGTTCAG-3' 5'-TTCACAATGGGAACCCTGTA-3'  
17 1049 5'-AACCCGATTTTCTTGCCTTA-3' 5'-TGAATGCCCCCAGAAAATA-3'  
18 1084 5'-AGAGTTGGGTGCCAAAACTT-3' 5'-GGGTATATATTTTCCCATTATTCC-3'  
19 691 5'-AACCAGGTAATTGGAAGTAAAAA-3' 5'-ACAGTTCTGCCAAAAATAAAACT-3'  
20 1061 5'-TGTTTACGGAAAAGTGAAACAAA-3' 5'-GGGGCTTCTGCATACTCAA-3'  
21 * 475 5'-GGCCAAATGTGTATATGAAAAC-3' 5'-CCATGACTGTAGAATAGGAGC-3'  
22 * 1783 5'-AGAGGACTTGGAGGTAAATATT-3' 5'-GACTCCTTGGTTTCCTTATTTA-3' 
5´-ATGTTACTGGAACAGAAGATG-3´ 
5´-CTGGTCCACATCTGGGTAAA-3´ 
23 * 1229 5'-AGGCTGGAGACTGTTGTAAAT-3' 5'-CTCAGGTTTCCATCTGGATTC-3' 5´–CTATCAACTCTGTTATGGTGGC-3´ 
24 708 5'-CCCTCTATGTGCTCATGCAA-3' 5'-TGGGGCCACTGTTCTTTAAT-3'  
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Table 4 Continued 
26 915 5'-CCACGCCCAACTAATTTC-3' 5'-CCTAGAAAATGCAGACCTTGAA-3'  
27 1057 5'-TGTTTTGGCCTTCTGATTTG-3' 5'-CATGGTGAGACCCTGTCG-3'  
28 755 5'-AGTAAGAAGTCCATGACAAAGTGT -3' 5'-TTTCCTGGGTTTCCTACAAT-3'  
29* 1881 5'-CATCAATTACAGTCGTACCTAT-3' 5'-TCAGCTTTAGCCCAGAATGC-3' 5´-GAGCAGTCTTATGTTACTGGGC-3´ 
30* 794 5'-TCATTTGCAGAAAGGAAAGG-3' 5'-AATTCAGAACAGGAGTAGTG-3'  
31 874 5'-TGCCTCTTTCCTACCTGACC-3' 5'-ATTTTTGTAAAGGACGAAAAACAT-3'  
32 1072 5'-AAAAACATGCCTATTAGGAAAAG-3' 5'-CGCATCTGAACATTCTCTGTC-3'  
33 1078 5'-CGGCCCTAGATGCAGTTTTA-3' 5'-AGATTCGCCCAGTTTCTGAG-3'  
34 1049 5'-AGAAGTCATTTGGCCCAGTC-3' 5'-GCTGAGGATTACAGGCTCATT-3'  
35 1046 5'-ACTTGGAGAGGGACGAAGAA-3' 5'-TCACAACCCAAATCCAGAAA-3'  
36 1044 5'-GCATAATTCGGAAGGGAAAA-3' 5'-TTATCAAGGCAACCCAAAGC-3'  
37 754 5'-GCCTGCATAAAGTACACAGGA-3' 5'-CTTCTCCACATCCTCAGCAA-3'  
*Primers from the study of Nickerson et al. (1998) 
 
The GeneAMP® PCR System 9700 thermal cycler with a heated lid (Applied Biosystems, Foster 
City, CA) was used for performing the polymerase chain reaction (PCR). The PCR reactions and 
cycling conditions are presented in Table 5. Gel electrophoresis by using 96-well pre-cast agarose 
E-Gel® 96 2% with SYBR® Safe (Invitrogen Corperation, Carlsbad, CA) was performed 
following amplification of each of the PCR fragments to check the success of the reaction. 
Reamplification was done for some of the samples that were failed in the initial amplification and 
regular 2% agarose gel with ethidium bromide (2µl) was performed after PCR reaction of this 
subset of reamplified samples to confirm the amplification.   
All the amplified samples were sent to a commercial sequencing lab where automated 
sequencing and capillary electrophoresis were performed on ABI 3730x1DNA Analyzers 
(Genomic Services of Beckman Coulter, Danvers, MA). Sequencing data received from the 
commercial lab was analyzed in our lab by Variant Reporter version 1.0 (Applied Biosystems) 
and Sequencher version 4.8 (Gene Codes Corporation, Ann Arbor, MI).  
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Table 5. PCR reaction and cycling conditions 
PCR Reaction (Total volume 25 μL) PCR conditions 
            DNA 3.0 μL 1. 95º C for 5 minutes 
 2. 95º C for 45 seconds 
3. 58-60º C for 45 seconds 
4. 72º C for 1 minute 
- Repeat steps 2-4 for 40 
cycles 
 5. 72º C for 10 minutes 
 6. Cool to 4º C 
           dH2O 12.25-13.75 μL 
           10x BufferGold 2.5 μL 
           MgCl2 (25 mM) 1-3.5 μL 
           dNTPs (1.25mM) 3.8 μL 
  Forward Primer (20mM) 0.4 μL 
  Forward Primer (20mM) 0.4 μL 
           AmpliTaqGold (5U/μL) 0.15 μL 
2.3   GENOTYPING 
While the sequencing was underway, we used the Hapmap database and Haploview program to 
determine the number of common tagSNPs that cover the entire gene and ~1kb flanking regions 
in whites. Seventeen tagSNPs were identified in Haploview (MAF ≥4%, r ²≥ 0.7)    using SNP 
genotype data of CEU population (Utah residents with Northern and Western European ancestry) 
(www.hapmap.org).  To date, we have genotyped 12 of them using TaqMan SNP genotyping 
assays. Table 6 lists the 48 variants that were captured by genotyping of 12 tagSNPs; 12 tagSNPs 
are highlighted in yellow.  Table 7 lists the assay IDs of the genotyped 12 SNPs in the entire 
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Table 6. Tagger results using SNP genotype data of CEU population provided from HapMap (MAF≥ 4%, r ²≥ 0.7)   
Bin Variants captured 
1 rs3916027, rs295, rs297, rs291, rs13702, rs326, rs327, rs331, rs320 (HindIII), 
rs301 
2 rs264, rs3779787, rs271, rs256, rs255, rs3779788, rs263 
3 rs11570891, rs15285, rs3735964, rs1059611, rs12679834, rs328 (Ser447X), rs325 
4 rs312, rs4922115, rs11570892, rs316, rs4921684, rs330 
5 rs10099160, rs319, rs3200218 
6 rs17410577, rs13266204 
7 rs258, rs253 










                                        Twelve screened variants are highlighted in yellow. 
        
Table 7. TaqMan SNP Genotyping Assays 
Assay ID 
 
LPL refSNP IDs 
 
Location Position Taqman Assay Type 
C__27500004_10 rs3779787 Intron 1 2335 Pre-made 
C__11856397_10 rs13266204 Intron 1 4424 Pre-made 
C___9642884_10 rs1534649 Intron 1 4060 Pre-made 
C__12104326_10 rs249 Intron 4 15425 Pre-made 
C___1842993_10 rs253 Intron 4 15836 Pre-made 
C__12104296_20 rs264 Intron 5 17599 Pre-made 
C___1842996_10 rs270 Intron 6 18095 Pre-made 
C__12104268_10 rs283 Intron 6 19517 Pre-made 
C__12104236_10 rs312 Intron 7 22416 Pre-made 
C___1843006_20 rs327 Intron 8 23955 Pre-made 
C___8804467_10 rs3289 Exon 10 3’UTR 27611 Pre-made 
C___8804485_10 rs1059611 Exon 10 3’UTR 28982 Pre-made 
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384-well plates containing dried whole genome amplified DNA was used in TaqMan genotyping. 
PCR amplification was performed using a PTC-200 MJThermal Cycler (Biorad) or a GeneAmp 
9700 (Applied Biosystems). After thermal cycling, Real-Time PCR system (ABI Prism 7900HT 
Sequence Detection Systems) was used for endpoint fluorescence reading of the plates. TaqMan 
reaction and thermal cycler conditions are given in Table 8. The remaining common SNPs are 
currently being genotyped by the medium-throughput Sequenom IPLEX genotyping assays. 
 
Table 8.TaqMan reaction and thermal cycler conditions 
TaqMan Reaction (total volume of 5 μL) PCR Cycling Conditions 
           dH2O 2.43 
   
   1. 95º C for 10 minutes  
   2. 95º C for 15 seconds  
   3. 60º C for 1 minute  
     -repeat steps 2-3 50x  
TaqMan Master Mix 2.50 μL 
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2.4   STATISTICAL METHODS 
Allele and genotype frequencies were determined by direct counting. Concordance of the 
genotype distribution to Hardy-Weinberg equilibrium was tested using a χ2 goodness-of-fit test 
for each variant. The variants identified by sequencing were analyzed by using Haploview to 
determine allele frequencies and their distributions among high and low HDL groups and their 
LD patterns. In the subset of sample that was used for sequencing, the χ2 test was used to 
compare the allele frequencies between the low and high HDL groups. For those SNPs that were 
genotyped in the entire sample, linear regression was performed to test for the effects of genotypes 
on the means of plasma lipoprotein lipid levels. The HDL-C and TG levels were transformed 
using normal log transformation to reduce the effects of non-normality. The significant covariates 
were identified using stepwise regression in both directions. The additive and dominant models 
were used for data analysis. The covariates included in the final model were sex, age, BMI and 
smoking. The R statistical software package (version 2.3.1, http://www.r-project.org) and 
Statistical Analysis Software (SAS) were used to perform all computations. A P-value of less than 
0.05 under one of these models was considered as suggestive evidence of association and a P-
value between 0.05 and 0.1 was considered as marginally significant (0.05≤P≤0.01).  
 
  27 
3.0   RESULTS 
3.1   DNA RESEQUENCING 
A total of 179 variants, single base substitutions or indels plus a microsatellite (tetranucleotide 
repeat marker) in intron 6, were identified in our study by complete resequencing of the LPL gene 
in 95 American NHW individuals falling in the upper (n=47) and lower (n=48) 5th percentile of 
HDL-C distribution. Table 9 shows a summary of the LPL variants identified in our NHW 
population sample. 
Of the 179 variants identified, 105 were found to be already reported in the Chip 
Bioinformatics which currently uses dbSNP build 130. Among these 179 variants, 88 had a MAF 
≥0.05, 54 had a MAF 1-5% and 37 had MAF ≤0.01 . Seventeen of those variants were insertions 
or deletions, and remaining 162 were single nucleotide substitutions. One hundred forty two 
variants were located in the introns (including the microsatellite), 7 were located in the 3’ 
flanking region, 8 were located in the 5’flanking region and 23 were located in the exons. Of the 
23 exonic variants, 3 resulted in non-synomous changes; aspartate9->asparagine (D9N) in exon 2, 
asparagine291->serine (N291S) in exon 6, and serine447->stop codon in exon 9, and 3 resulted in 
synonymous changes; valine108->valine in exon 3, glutamic acid118->glutamic acid in exon 4 
and threonine361->threonine in exon 8. 
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The remaining 17 exonic variants were located in the last exon 10 that codes 3’UTR region 
(Table 9). Of the 17 insertions and deletions, only one of the insertions was located in the exonic 
region but it was in 3’UTR and so did not affect the protein sequence. The range of indels sizes 
was 1-20 base except a 697-base deletion identified in intron 2. 
We identified 74 variants that are not reported in the dbSNP build 130; 22 of these new 
identified variants had MAF ≥0.05, 52 had MAF <0.05 and 33 had MAF ≤0.01. Of 74 new 
identified variants, 4 were located in 5’ flanking region, 62 were in introns, 5 were in 3’UTR and 
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Table 9. LPL variants identified in our study for the NHW population 
LPL variant Alleles Location refSNP   Amino Acid Change MAF Call Rate 
ID       % 
208 T>C 5' flanking  rs1470186   0.016 98.90 
351 C>A 5' flanking      0.005 98.90 
428 G>A 5' flanking  rs73667465   0.016 98.90 
549 C>T 5' flanking  rs17091742   0.016 98.90 
958 G>A 5' flanking      0.005 95.80 
1088 G>T 5' flanking      0.005 97.90 
1090 T>G 5' flanking  rs1800590 (-T93G)   0.011 98.90 
1130 G>C 5' flanking      0.005 97.90 
2335 G>T Intron 1 rs3779787   0.122 98.90 
2913 T>C Intron 1     0.005 95.80 
3558 G>A Intron 1 rs34309063   0.247 100.00 
3964 G>C Intron 1 rs17410577   0.239 98.90 
4060 G>T Intron 1 rs1534649   0.430 97.90 
4424 A>G Intron 1 rs13266204   0.263 97.90 
4621 C>G Intron 1     0.021 100.00 
4948 C>G Intron 1 rs6997330   0.022 97.90 
5094 C>G Intron 1     0.005 97.90 
5107 C>T Intron 1     0.005 96.80 
5118 A>T Intron 1     0.022 95.80 
5200 C>T Intron 1     0.006 91.60 
5531 G>A Intron 1 rs1031045   0.016 96.80 
5772 A>G Intron 1 rs60633545   0.016 98.90 
5949 T>G Intron 1     0.137 100.00 
6383 G>T Intron 1     0.005 100.00 
6435 G>C Intron 1     0.005 97.90 
6477 T>C Intron 1     0.005 98.90 
6553 C>T Intron 1 rs59254395   0.016 100.00 
6554 A>G Intron 1 rs56043715   0.016 100.00 
6821 C>T Intron 1 rs10104051   0.426 98.90 
7130 T>C Intron 1 rs28615996   0.021 73.70 
7131 T>G Intron 1     0.007 75.80 
7313 G>A Intron 1 rs28645722   0.016 98.90 
7388 C>G Intron 1 rs28575919   0.016 100.00 
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Table 9(Continued) 
7503 T>C Intron 1 rs6999612   0.016 100.00 
7512 C>T Intron 1 rs3779788   0.121 100.00 
7556 T>C Intron 1 rs59811201   0.016 89.50 
8221 A>C Intron 1 rs7000460   0.018 84.20 
8250 G>A Intron 1 rs59630933   0.019 97.90 
8415 T>A Intron 1 rs56321069   0.183 100.00 
8467 C>T Intron 1     0.005 100.00 
8516 delG Intron 1     0.011 50.50 
9015 A>G Intron 1 rs28445964   0.021 68.40 
9024 T>C Intron 1     0.008 98.90 
9130 T>A Intron 1 rs13252357   0.005 98.90 
9411 A>C Intron 1 rs28689946   0.016 98.90 
9418 G>A Intron 1 rs28582042   0.016 98.90 
9589 C>T Intron 1     0.016 98.90 
9696 G>T Intron 1 rs73667468   0.016 97.90 
9914 T>G Intron 1 rs73667469   0.016 100.00 
10127 G>A Exon 2  
(non-synonymous) 
rs1801177(D9N) Aspartate9> 
Asparagine    
0.016 100.00 
10632 C>T Intron 2     0.005 94.70 
10912 A>G Intron 2     0.022 94.70 
10987 C>A Intron 2     0.122 96.80 
11050 T>C Intron 2 rs7016529   0.016 96.80 
11090 C>G Intron 2 rs8176337   0.190 98.90 
11228 T>C Intron 2     0.005 96.80 
11574 G>A Intron 2 rs34123038   0.049 100.00 
11600 G>C Intron 2     0.011 100.00 
11760 A>C Intron 2 rs73667470   0.016 100.00 
11888_11889 insA Intron 2     0.011 95.80 
12224_12920 del697 Intron 2     0.005 98.90 
12449 G>A Intron 2     0.117 97.90 
12484 C>A Intron 2     0.048 97.90 
12550 G>A Intron 2     0.118 95.80 
12810_12829 dup20 Intron 2     0.126 95.80 
12853_12854 Ins16 Intron 2     0.055 95.80 
12861_12864 del4 Intron 2     0.060 95.80 
12878_12889 del12 Intron 2     0.005 100.00 
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12884_12887 del4 Intron 2     0.016 100.00 
13003 G>T Intron 2     0.053 100.00 
13639 G>A Intron 2     0.011 98.90 
13854 G>A Exon 3 
(synonymous) 
  rs1121923(V108V)       Valine108> 
        Valine  
0.016 100.00 
14114 T>C Intron 3 rs73667472   0.080 100.00 
15206 C>A Intron 3 rs343  0.042 100.00 
15245 G>A Exon 4 
 (synonymous) 
rs248(E118E) Glutamic acid118> 
Glutamic acid 
0.047 100.00 
15425 T>C Intron 4 rs249   0.095 98.90 
15449_15450 Ins2 Intron 4     0.063 98.90 
15653 delA Intron 4     0.410 92.60 
15836 C>T Intron 4 rs253   0.410 100.00 
16316 C>G Intron 5 rs254   0.074 97.90 
16320 T>C Intron 5 rs255   0.105 96.80 
16386 C>T Intron 5 rs256   0.118 97.90 
16442 G>C Intron 5     0.005 97.90 
16563 T>A Intron 5     0.016 93.70 
16671 G>C Intron 5 rs258   0.409 100.00 
17231 C>T Intron 5 rs263   0.135 100.00 
17476 A>C Intron 5     0.005 95.80 
17599 G>A Intron 5 rs264   0.116 60.00 
17948 A>G Exon 6  
(non-synonymous) 
rs268 (N291S)       Asparagine291> 
Serine 
0.033 92.60 
18065 T>G Intron 6     0.009 91.60 
18086 T>G Intron 6 rs269   0.119 96.80 
18095 C>A Intron 6 rs270   0.201 100.00 
18121 G>A Intron 6 rs271   0.109 100.00 
18297 A>C Intron 6     0.005 97.90 
18395_18396 InsT Intron 6     0.121 100.00 
18462 T>G Intron 6     0.005 98.90 
18621 C>T Intron 6     0.005 100.00 
18708 T>C Intron 6 rs276   0.021 95.80 
18822 T>C Intron 6 rs277   0.232 97.90 
18942 G>A Intron 6 rs278   0.211 97.90 
19442 A>T Intron 6 rs281   0.242 95.80 
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19445 C>G Intron 6 rs282   0.129 96.800 
19517 C>T Intron 6 rs283   0.161 100.00 
19608 C>T Intron 6 rs285 (PvuII)  0.407 97.90 
19675 A>T Intron 6 rs286   0.060 95.80 
19815 G>A Intron 6     0.005 97.90 
19975 A>G Intron 6 rs287   0.172 100.00 
20038 T>C Intron 6 rs289   0.159 100.00 
20080 C>T Intron 6     0.005 100.00 
20271 T>C Intron 6 rs291   0.163 98.90 
20363 A>T Intron 6     0.053 100.00 
20505_20506 insA Intron 6     0.163 100.00 
20544 T>C Intron 6 rs294   0.080 100.00 
20657 A>C Intron 6 rs295   0.163 98.90 
20663 G>A Intron 6 rs296   0.005 97.90 
20790 T>C Intron 6 rs297   0.163 91.60 
21125_21128 del4 Intron 6     0.005 87.40 
21353 T>C Intron 7 rs301   0.172 86.30 
21780 T>G Intron 7 rs304   0.103 86.30 
21820 A>G Intron 7 rs305   0.108 97.90 
21895 T>G Intron 7 rs308   0.012 94.70 
21965 C>T Intron 7 rs310   0.006 93.70 
22044_22047 del4 Intron 7     0.075 92.60 
22416 G>C Intron 7 rs312   0.072 100.00 
22461 G>A Intron 7 rs314   0.180 92.60 
22514 T>C Intron 7 rs315   0.011 92.60 
22855 C>A Exon 8 
 (synonymous) 
rs316 (T361T) Threonine361-> 
Threonine 
0.079 88.40 
23190_23191 del2 Intron 8     0.500 86.30 
23192 G>T Intron 8     0.068 88.40 
23388 C>G Intron 8 rs318   0.018 90.50 
23395 A>C Intron 8 rs319   0.293 93.70 
23496 T>G Intron 8 rs320 (HindIII)   0.185 94.70 
23573 T>C Intron 8     0.017 95.80 
23636 A>C Intron 8 rs322   0.170 98.90 
23747 T>C Intron 8 rs325   0.067 98.90 
23858 A>G Intron 8 rs326   0.206 100.00 
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23955 T>G Intron 8 rs327   0.192 90.50 
24143 C>G              Exon 9 
   (non-synonymous) 
rs328 (Ser447X) Serine447-> 
Stop codon 
0.005 100.00 
24505 A>G Intron 9 rs329   0.016 98.90 
24573 T>C Intron 9     0.005 100.00 
24815 G>A Intron 9 rs330   0.111 100.00 
24824 G>A Intron 9 rs331   0.122 100.00 
24852 T>C Intron 9 rs12679834   0.080 100.00 
24899 C>T Intron 9     0.016 100.00 
25005 A>G Intron 9     0.005 100.00 
25049 G>A Intron 9     0.063 98.90 
25320 C>T Intron 9     0.005 95.80 
25335 C>T Intron 9     0.079 98.90 
25352 A>C Intron 9     0.079 91.60 
25844 T>G Intron 9     0.074 95.80 
26201 T>G Intron 9     0.077 96.80 
26234 T>G Intron 9 rs10099160   0.282 98.90 
27000 C>T Intron 9     0.029 98.90 
27160 T>A Intron 9     0.027 98.90 
27229 C>T Intron 9 rs11570891   0.082 97.90 
27249 G>A Exon 10-3' UTR rs4922115   0.085 98.90 
27611 T>C Exon 10-3' UTR rs3289   0.016 95.80 
27688 C>T Exon 10-3' UTR     0.005 95.80 
27783 A>T Exon 10-3' UTR     0.011 95.80 
28036 A>G Exon 10-3' UTR rs11570892   0.101 100.00 
28067 A>T Exon 10-3' UTR rs3208305   0.203 100.00 
28093 C>T Exon 10-3' UTR rs1803924   0.082 100.00 
28382 C>T Exon 10-3' UTR rs1059507   0.110 100.00 
28407 C>A Exon 10-3' UTR     0.026 100.00 
28464 C>A Exon 10-3' UTR rs3735964   0.079 100.00 
28490 A>G Exon 10-3' UTR rs3200218  0.279 100.00 
28524 C>T Exon 10-3' UTR   0.005 100.00 
28911 T>C Exon 10-3' UTR rs13702  0.200 100.00 
28982 T>C Exon 10-3' UTR rs1059611  0.079 97.90 
29046_29047 Ins2 Exon 10-3' UTR   0.079 100.00 
29086 C>T Exon 10-3' UTR rs15285  0.200 100.00 
29088 C>A Exon 10-3' UTR rs3866471  0.105 100.00 
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29287 G>A 3' flanking rs3916027  0.184 100.00 
29315 T>G 3' flanking rs9644636  0.339 100.00 
29474 C>T 3' flanking   0.026 98.90 
29487 T>A 3' flanking rs4921683  0.105 98.90 
29547 C>T 3' flanking rs4921684  0.105 98.90 
29557_29558 InsA 3' flanking   0.005 98.90 


















  35 
3.1.1   LPL Annotated Sequence 
Figure 4 depicts the variants identified in LPL within a color FASTA representation of the 
annotated reference sequence adapted and modified from the CHIP Bioinformatics database 
(http://snpper.chip.org). The color code for the reference sequence is as follows: green for 5’ and 
3’ flanking regions, grey for introns, black for exons. Capital letters are used to show coding 
bases and small letters show the bases in the UTR and flanking regions. The variants identified in 
this study also listed in dbSNP build 130 are shown in blue font with refSNP ID; the variants that 
are identified in only our study are shown in red font. The 197 variants which were already 
reported in public databases but not identified in this study are shown in grey font. The small 
deletions and the insertions identified in our study are shown by highlighting the region in yellow. 
We identified a large deletion in intron 2 which was not reported before in any public databases 
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 19,839,852      ataaat atagtagatt ggaggttctg atttgatgag ccagtttctc 
 19,839,898  agccataaac tgagaggggg ttggggatac acttcattgt ccttcctggc 
 19,839,948  taatgtaaat cccttatatt taaaaagata tttaaaagta ttccaagcat 
 19,840,008  tttggcagaa aagcatagta tctaatgtta tttttttctt attttatgtg 
 19,840,058  catgcctctt atccatttaa aaatagcttt actgacctat aatttacaca p.208/rs1470186-[T/C] 
 19,840,108  ctatataatt ctcccattga aagtgcataa ttctgttgct tttagtatat 
 19,840,158  ttacagagtt gtgcagcatc agcataatgt aatctagaac attgtcatca 
 19,840,208  actaccccca aatctctatt cttcccttcc cctattaatt acccagcccc p.351-[C/A] 
 19,840,258  aggcaagcac tgatctactt ttggtctcta tggatttgtc tatttgtgga p.428/rs73667465-[G/A] 
 19,840,308  cactttaaat ggaatcatac aatatgtgtc ttttgcgact atcttctttc 
 19,840,358  acttatcata actcaatacg gctttagatt atttgacctc gatgttctgc 
 19,840,408  ctctgaacat aaaatattat ccttgcattc cttgatgagt ttgaggattg p.549/rs17091742-[C/T] 
 19,840,458  agaataattt gcatgagaca aaaattagaa actagttaga gcaagtaggc 
 19,840,508  ttttctccat cacataagct gatccatctt gccaatgtta aaacaccaga 
 19,840,558  ttgtacaagc acaagctggg acgcaatgtg tgtccctcta tccctacatt 
 19,840,608  gactttgcgg gggtggggat ggggtgcggg gtgagtgagg gaggactgca 
 19,840,658  agtgacaaac aggattcgtc aaaagagagg tgtattaaag tgccgatcaa 
 19,840,708  atgtaattta acagctaaac tttccctcct tggaaaacag gtgattgttg 
 19,840,758  agtatttaac gtgaatcgat gtaaacctgt gtttggtgct tagacagggg 
 19,840,808  gcccccgggt agagtggaac cccttaagct aagcgaacag gagcctaaca p.958-[G/A] 
 19,840,858  aagcaaattt ttccgtctgc cctttccccc tcttctcgtt ggcagggttg 
 19,840,908  atcctcatta ctgtttgctc aaacgtttag aagtgaattt aggtccctcc p.1088-[G/T];p.1090/rs1800590-[T/G] 
 19,840,958  ccccaactta tgattttata gccaataggt gatgaggttt atttgcatat p.1130-[G/C] 
 19,841,008  ttccagtcac ataagcagcc ttggcgtgaa aacagtgtca gactcgattc 
 19,841,058  cccctcttcc tcctcctcaa gggaaagctg cccacttcta gctgccctgc Exon 1 
 19,841,108  catccccttt aaagggcgac ttgctcagcg ccaaaccgcg gctccagccc 
 19,841,158  tctccagcct ccggctcagc cggctcatca gtcggtccgc gccttgcagc  
 19,841,208  tcctccagag ggacgcgccc cgagATGGAG AGCAAAGCCC TGCTCGTGCT 
 19,841,258  GACTCTGGCC GTGTGGCTCC AGAGTCTGAC CGCCTCCCGC GGAGGGGTGG 
 19,841,308  CCGCCGCCGA CCGTAAGTTT TGCGCGCAAA CTCCCCTCCA CCTGCAGACC Intron 1 rs11570895  
 19,841,358  CGGCGGGTGG CCACTGCCAC CCGAACTGAG GATGAGAAGA AGGAAGTTGG 
 19,841,408  AAGGGGCGGT GGATGCGCCC AGGGACTCTC CCAGCCTGGG CTCTAGCCCC 
 19,841,458  GAAACGGTCC CCGGAGTGGG ATCCAGGAGG GGCCGGGAGG GAATCTCCTC 
 19,841,508  CCGATCGTGA AGCGGCGGCG CCCAGTTCCC GCTTTTTCTC TCTGCCGGGT 
 19,841,558  TCCCGCGCTA TCCCTTCCAC TCTGGCTGGG ACCGCGTTCC CGGGCTCGCA 
 19,841,608  GGCTCCGCCG GGGAGGTTCC GGGGTGTGGG GGCCGGGACG GCGGAGGCGG rs2898492 
 19,841,658  GGAGTAAGGG CCCGGCTGGC GGTGACCTGC AGTCACCTCT CTGCCGGAGG 
 19,841,708  GGCCCTGGAA TGAAAGGCGC GCGGGCCAAG GTGACCTCGC CTTGGTTGGC 
 19,841,758  ACTGCGGCTC AGCCCCCGCC CGGGGACTCG CGGGCCGACT GTGGCCCCTT 
 19,841,808  CTGGGGAAGC CGGGGCGCGG GGAGGCGTTC CGGGCATCTC AGCCGCACGG 
 19,841,858  GGTACGCTCG CCCTCGGCGG GGCCCCTCGC TCCGCTGTGG GAGTGGCAGT 
 19,841,908  GGGTGTCGGG GTGGAGAAAG TACGCGTGGC GCGGAGTCCT GGGGACGCGG rs7839976 
 19,841,958  CGTCCCACCC GCTCTGGGGA GCCCCGGACT CTCTCCAGCT TCCAGGCTCG 
 19,842,008  CATGCCCCTC TTTTCTTAGT GCCCTGAGAA CCCAGCGAGG GGCTGACCCT 
 19,842,058  CCCGAAACCG TGGCGCAGCC ACCAGCAATC TGTGGTCGCC GACTCGGGGG 
 19,842,108  GTTGCCAGGT CTGCGTTTGG CCACCCTTTC TGTCCTGGGG GCTGAGGTCA 
 19,842,158  GCTCCGGGCG CCCGGCCCCG CCGCGCGGCT GCGAGCACGT GGGGTTGACG p.2335/rs3779787-[G/T] 
 19,842,208  GGCGCCGCGT GGAGGCAGCG AGCACAACGG TGGTCACCGC CGCCAGGGAA 
 19,842,258  CCGCCCGCTC GCTGGGGTCC AGGCGTTCGG GGCCAAATGA GAATGTCTCA 
 19,842,308  GACCTGTCCG CAATGGAGGC AGCCTGCTTA ATTCGAACCT CGATTCAGTA 
 19,842,358  AACATGCAAC AGCAGCATAG AGAGCAGCTG AAGCCATTCA TAACACGGGA 
 19,842,408  CAACATTTCC TTTTTTCTTC CATGCTGGAA TTGCAATTAG GGCGGTGTCG 
 19,842,458  CTTGGATGTG CTCTCAGGCG GCACGTCCCC AGCGGTTCAA GTTATAATAG 
 19,842,508  AGTCTCTCCA TAGCTTTGAT GGCCGCTAAA CGTTTGTTTT ATTTTGGCAT 
 19,842,558  TAATTTGTGA AACATTTTTG TTAGGTTAAA AAACAAAAAG TTGGCAGGGA 
 19,842,608  GCAGTGGCTC ACCCATGTAG TCCCAGCACT TCGGGAGGCC GAGGCCGGAA 
 19,842,658  GACAGCTTGA GCCCAGAAGT TCGAAATCAG CCTGGGCAAC ATAGGGAGAC 
 19,842,708  ACCGTCTCTA TAAAAAAAAA ATACAAAAAT TAGCCGGGCG TGGTGGCCTG 
 19,842,758  TGCCTGTGGT CCCAGATAGT CAGCAGGCTG AGAGATCACT TGAGCCAGGG p.2913-[T/C] 
 19,842,808  AGTTTCAGTA GACTGCAGTG AGCTGTGATT GCCCCACTGC ACTTCATCCT 
 19,842,858  GGGTGACAGT GAGACCCTGT CTCATAAAAT TAAAACAAAA CAAAACAAAC 
 19,842,908  ACTAAGTATA GATTCCATCA AAGCAAAATT GGATAAGAAA AAAAGTATCT 
 19,842,958  TTTCTATTGG ATCAGTTTGA AAACACTGGA GAGTTGATGA GAAAGTCTTC 
 19,843,008  AACATCTTAG GTGGGGTATG TTTCGTATGT TTCCCTTCGT ACTGCTTAAT 
 19,843,058  GCTGACAAGA AGATGGTAGG AGCCAACTCC AAATTCTTAT TTCAGAAAGC 
 19,843,108  ACACCATAGA ATAACGTCAT TTTCATTGCA AAACAAGCAC CGAAATATGT 
 19,843,158  CATCACATTC AAGTTTTTCC TAGGCTCCCT TACAGGTTCA AGATCCTAAA 
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 19,843,208  TTCTTGGGAG TCAGTGTCAC CTCTCTGGGT TTAGGTTCCT CAACTCTGCA 
 19,843,258  ATGAGTTTGG ATGAGGCCAA TGTTCTCTGA GCCTGGTGTA ACTCTTGCCT 
 19,843,308  CTTTAAGTGG ACACTTATGT GATTAATTAG TTTAATTGAG TTGTAGCCAA 
 19,843,358  CACATGCTTT TCCTAGCTGT AAATATATTA AGGAAGGATT ATTTCCAAGT 
 19,843,408  AGACTGGAAA CGATGCCCTC CCATCCCCTC CACTTTCACT CTACTCACCC p.3558/rs34309063-[G/A] 
 19,843,458  AATATATCAT GCCTCTCCCA TCACAGCAAC TTTCTCCCTC TTTCTCCTCC 
 19,843,508  AGATGCATTC ATCTAGGAAG GTAAGAATTT CAGGGAGAGA AAGATGTCAC 
 19,843,558  CGTGGTAGAA AGACAGGGAT CACCTCCTCT GGGCTCTTGA GTTTACTTAT 
 19,843,608  TCATTCTGGA TTCTTTCTAA CAAGAATATG AGGACAAGAG GCACTGTCCT 
 19,843,658  CAGGCACTTC GTCCTGGGAG CCACCACCAT CTCTGCATGG CCCCAATTAG 
 19,843,708  GAAACGTGAA GAGCTAGGAG AGGGAGAGTA TGGTCAGTGC TTAGCAGCTG 
 19,843,758  AAGTTCCACT TGCCTGGCCA TCGTGAATTT CCAGGCTGTC TTCTGAGTTG 
 19,843,808  AACATGATGG CAAAGGAGAG CAAAATAGCA GATGTCACTG AAGGAGAGCT p.3964/rs17410577-[G/C] 
 19,843,858  CAGCGAGGGA GTGATTGATT AATAGCTGTA TTGAAAGGTG GGAGTCAGGT 
 19,843,908  ACGGGGGAAG AGCGGCGATG GAAAATTTTC GCTTTCTTTC AGCAGCTTAT p.4060/rs1534649-[G/T] 
 19,843,958  TTTTAACTCA GCTTTCTGTT CTTGCTTTAT TATGGAGGAA AAATTGGGCC 
 19,844,008  ATAGAGTTTA CTGCCTTATG CCAGATTGTT CAAGAAAATG CCTTGCAACT 
 19,844,058  TACAATATTT TGCAGCTAGT TTCTTCCGTG ACCACCACAA AGACTGCATT rs73667466 
 19,844,108  GACTTAAATA TGAAGATGTT CCAGCCATCA AAATGATGGT TGGTGATGAT 
 19,844,158  TTTGGATCAC AAAGTGTAAG GAAAGTATTC AAGACATGAG TATCATGATT 
 19,844,208  TTTTAAGGTC TGGATGAAGA GACCATTTGG ATTTACTAAT AAGGTAAATT 
 19,844,258  CCAACTTTTA TGGCAATAAA AACAACAAAA ACACTTATCA GTGTAAAGCT p.4424/rs13266204-[A/G] 
 19,844,308  TTGGGATCAT CTATCCATTA AATGAGTTTG TCACCACAGT GAACTAAATA 
 19,844,358  CCTTTTATCA ACAGAGACTT TCTAACCTGG GAGTAAAATT CTTGTCACAG 
 19,844,408  TGCTTTTGTC ACATTCTGTC TTTGCAAAAG TTGAAGGCTC CAATAGTTTC 
 19,844,458  TGAAGGACTA ATAGGATAGG GTTCCAACTT ACTCAGAGGC TAAGAGTTTG p.4621-[C/G] 
 19,844,508  AAATTTACTC TGAACGATGT CTGTTCACTA GACTGCGTGA CTGCAGTTTG rs58877654 
 19,844,558  CTGTCTTGTG GCCATTTTAA GATTGTCTGT GTGCACTGAC ACCATTTGCG 
 19,844,608  TACTCAACAA CAGGTATCTA CTAGGAAGGA AGGAATGGAT TATCTTAGGT rs10503668 
 19,844,658  GCTATATATA TATGTAAGTT CTGCCGGAAG TGAGCCTATT AAACTTGTGC 
 19,844,708  CAATTCATTC CTTTTGCTCT TCCCAGTCTG TGCTCTCAGA ATGATCAAAT 
 19,844,758  GCTATCTAAG TAGTGTGGTG ATTTTGACTG TTTGAATGAA TAAACGAAAA 
 19,844,808  CGTCTCCCAC CATTATTTGA CAGTAGAATA GAACAAAGAT GACCCAGTTG p.4948/rs6997330-[C/G] 
 19,844,858  GCGTGGCCAC ACTGTGTCTA ATCCAGCCAC CTTGCTCACA GCACTCAACC 
 19,844,908  CACTTTGGTG TGTGCGCTCA TCTGTATTTT CGTAAATGTT GAAGTCTCTT p.5094-[C/G] 
 19,844,958  TCTATGCAGT CAGGTAGGGG TAATACCATT CTGGCTTGGA TTAATTTGAG p.5107-[C/T]; p.5118-[A/T] 
 19,845,008  TGTAGTACAA AGTTTAGAGA AGCTTTTAAG TAGCATGAAA AGTCAGATGC 
 19,845,058  TTTCGGAGGG ATGGTGGTGA ATGTAGGTAA ATGGATCTGC ACTTAGAGAT p.5200-[C/T] 
 19,845,108  CCTCAACAGC CCTTCATTCA AGATACAGCT ATCATGACAT CAATAATGTA 
 19,845,158  CCTTTGAAAA AAAATTGGCT GCAGAATTAA TTACGGTGAA AAACAGTATA 
 19,845,208  GGAGTTAGCA CTTACATTTT AACTAAAAAG AATAGCGTCC CCATGTTTAT 
 19,845,258  TCAGCCCTCC CTCCAATAAA ACAATTGTTG GCAAAGTAAT CATGGACTTT 
 19,845,308  CATTGTGTTA GTTTGAGACA ACTGGATGTT TCCATTTGCC ATCCTCAGCA 
 19,845,358  ACAAGAAGAA AGTAGTCTCA GATTAACCAG GTAAGTATTT TGTATTTCAC p.5531/rs1031045-[G/A] 
 19,845,408  TTAAAAAATC TTGACTGAAA TATGCCTATG TGATGACACT CAACCAAATT 
 19,845,458  ATTTCATTAA CCAGTCCACA AGATCTCCTT AAATAATGAT GGCTTATTCA 
 19,845,508  CACTTGATGG TCTCATTCAG TGGGGCAATT TTAATACACA TCTCTGAACC 
 19,845,558  TATTTTTTAA CCCCTCTTTT TCAGTAGTGT GGAAGGTTAG CCCTAATATT 
 19,845,608  GGAGAAAATT CAGGGTAAAA TTCAGATGAT TCATACAGGA TTTATTTTTC p.5772/rs60633545-[A/G] 
 19,845,658  CTATTCCATT AATAAAACAA CTTTTATAAA AATAAAAAGT AGGCTGGCAC 
 19,845,708  AGTGGCTCAC TCCTGTAATC CCAGCATTTT GGGAGGCCGA GGCGGGTGGA 
 19,845,758  TCATGAGGTC GGGAGTTCAA GACCAGCGTG GCCAGGATGG TGAAACCCCA 
 19,845,808  TCTCTACTAA AAATACAAAA ATTAGCCAGG CGTGGTGGCA GGCACCTGTA p.5949-[T/G] 
 19,845,858  ATCCCGGCTA CTCGGGAGGC TGAGGCAGAG AATGGCTTGA ACCCAGGAGG 
 19,845,908  CATAGGTTGC AGTGAGTCAC GATCGTGCCA CTGCACTCCA GCCTGGGTGA 
 19,845,958  CAGAGCAAGA CTCCGTTTCA AAAAATAATA ATAAAATAAA ATGAAATAAA 
 19,846,008  GTAAAGCTGC ATGTTAGAGA AGTCAAGAGC ATTACTTACG TTAGAATATC 
 19,846,058  TGAACAGACC AATCAATTCA GTCTGATCAT GATATTGATG TTTTTCTTCA 
 19,846,108  CCAAATCGAC CACATCAGTA ATTCACTTTG TTCTTCGATA TCCTACAGAC 
 19,846,158  ACTGCCTGAG TCGATAACTA TGACTATCAG TCTCAGAGAG CAAATGAATT 
 19,846,208  ACTGAGGAAG CCCTGTAGGA GTGAGAGAAA AGGGGGGAGA GAGAGAGAAA p.6383-[G/T] 
 19,846,258  GGGGTGGGGG GATAACAGGA GAACAGAAAT TCCAAAGAGA ATTGCATTCT p.6435-[G/C] 
 19,846,308  CATTGAGTTC TTGTACCTCA TGTCATTGCA TAAATGTTCA TCTTACTCAC p.6477-[T/C] 
 19,846,358  GTGATGACTT TGATCTGCCT TTAAAGCACC ATCTGCTGCT TTCCTGGGAT 
 19,846,408  GCTCAACACT TCCCTCTTTC TAGCAACAAG AATTACCACT CTTCCCCTCT p.6553/rs59254395-[C/T];p.6554/-
rs56043715-[A/G] 
 19,846,458  ATACATTTAT CTTTCTCTAC GTGCTTTAAC TTCTCAGCCT AATTTCGTCT 
 19,846,508  CTGTGAGTTA TTATCTATGT TAGAATAAAT TCTTTGTCTT TGTTTACACA 
 19,846,558  CTCAGATTTG TAGTTATTTA TTTAGGAATT TAGGAATAAA GATTCCATAG 
 19,846,608  TCAGGAAAGG CACAATTTAT AACTTGCGTG TTACCCAAAA CTCTCCCCTA rs61274012  
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 19,846,658  AGGGCTTAAT ATGGACATTT CTGACGAGGC CTGATGGGCA GGTGGTACGG p.6821/rs10104051-[C/T];rs73667467 
 19,846,708  TGATGCTAAG TTAAATTCAG AATGAAGGCC TGCCTTTCCT TCCCTCCTTC 
 19,846,758  CTTCCCCTTC CCCTTCTTCC TTCCTTCCTT CCTTCCCTCC ATCCCTCCCT 
 19,846,808  CCTGTACTCC TCTTCTTTCT CAATTCTAAG GTGGCCTTAA TTTCTAAGGG 
 19,846,858  ACATGGCAAA AGACAGTCTA GTTGGATGAG TGCAGTCACT AATATTATTT 
 19,846,908  CCATGTATGG AAAATAACTG TTTCCTTAGT AACAATTGCA TCAAATCAGT 
 19,846,958  TCACCTGCTG CCCAATAGCA ATCACAGGAT GCATTGGGAC AAATAAATAT p.7130/rs28615996-[T/C];p.7131-[T/G] 
 19,847,008  ACTGACTGCC CCACAGCCAC ATGGTCTAAG TCAGTTACTG GAGAGCTGAC 
 19,847,058  TGAAGTTTGG GAAGCATATT CATCTTACGA CACTGAGACA TCCTCGGGGG 
 19,847,108  GTTGCAAACA CAGGTAGTGT GAAAATTATC AGAACATCCA AGAAAAGGAA 
 19,847,158  AGTTTGACTA AGTGCCGATA AGATTTATGA TGTCATGTCT GACATAGAAT p.7313/rs28645722-[G/A] 
 19,847,208  TGAAACCATC ACAGAGCACA TAGAGTGGTA TATTTTCCTG TCAAATGAAA p.7388/rs28575919-[C/G] 
 19,847,258  ATCATTTTCT TTAAAAGTGA AATGAAAGTC TCTAAATACA AATTTACTAG 
 19,847,308  AGGATGTGTA AATTTCCTAC TTTTCATTAC ATACTCTGGA CCCAACAGAG 
 19,847,358  GGAAATTGGA GCTGTCAGTG AGCCATACAT GCAATCTGGT ACAGGATCTA  p.7503/rs6999612-
[T/C];p.7512/rs3779788-[C/T] 
 19,847,408  TGGATTGAAT AGACTTTTTT TCATGGAACT ACACAAAGCC AGTCTTAGTC p.7556/rs59811201-[T/C] 
 19,847,458  ATTTCAAAGA AAATTTGTGG TCATTTCAAA ACCACCAGCA ATTCCAGGGA 
 19,847,508  CACCAAGTTG CATAATTCTA GGGGAAAGTG GACTAAAAGT GAATGGCAGC 
 19,847,558  CTCTGGAGTT ATACTGAGCA TTATTCTTAA AATGTCAATT TGGCAAATAG 
 19,847,608  GTGGTAAGCG AGATCTGTCT GCCAGATTGT TCACATCATC TCTGCTTTAA 
 19,847,658  AAAGATTGAT CATAGAATAT GTTAAAATAA GACCTGTGGA GAGGAGGTAT 
 19,847,708  GAGCTATTTA AGGTGGAAAG GTGTGGGAGA GGGTGAAATT AGTTTTAAAT 
 19,847,758  TTTCTAAAGC ACTTTTTAAC AGGAAAAGAA GTTCTTGGGC ACTGAAGGCA 
 19,847,808  GAATTAGATT AAAAGTATTC AATACTCTTC CATTATCAGA GAAATAGTAA 
 19,847,858  AGCTACTAGA GTGCTTTCTG GTTGGGAAGG AAGAAGGCTA CCAACATCTT 
 19,847,908  CAAATAAAGA TGAGAAGTAG AGCATATTCT TGGTGGATGA ATGGATTCAC 
 19,847,958  GTGTACTTTT ACTATATGCA AATGAAAAGA GCTTTAAAGA TCAATAGTTT 
 19,848,008  AGCAAGACTC TTATTTGAAT AAGTGATCTT GGAGTGTTTA CCCATTGTAA 
 19,848,058  CAAAACTCCT TTTCTCATAA TTAGAATCAT TAAGAAATTT CTCCTACATT p.8221/rs7000460-[A/C] 
 19,848,108  TTAGATGACG GAGGTGTGTG TGCACGTGTG TGTGTATGTG TGTGTGATCA p.8250/rs59630933-[G/A] 
 19,848,158  ACTCATTGCA TATTTCTTAA ACCACAATAT TGTTTAAGGA ATTTTAGAAA 
 19,848,208  ATAATTACTC AATAGGAAAA TGTTGGCCAA TCCTCAGATA TTTAGATAAG 
 19,848,258  GCTGATTCAA ATGCCTATTC TTTCACTGTT CTCACTATGA CACTCTTATT p.8415/rs56321069-[T/A] 
 19,848,308  TTTATTATTG GCCTGACTTC CGCAGTTATT TTGAAGTTAC AGATTTTTAA p.8467-[C/T] 
 19,848,358  ATTTTGAGTT GAAAAAAAAG AGCAAATTTA GATTAAGGAA TGAGAAGTAG p.8516-[delG] 
 19,848,408  TCCTCGCAGC CTCATGAATC TCCTGAAATT TCGAACGGCA AAATCTAAAA 
 19,848,458  TCTACAAGTT ATTACCTTCT TACAGTAAAT AGGTGGGTGT TATGGGTCGT 
 19,848,508  TTTCTTTAAC TTCTTTACTT GAAAAGGAAT TAAATGATTT CCCTTTAACA 
 19,848,558  TAACTTCCCT TTGATTGTGC TCTGCTTCAT GAAGTCTGAT TTTATTTGCA 
 19,848,608  ATATAATTTA CTTCAACTAT TCACTGTACC CCATGAAGAT TCAGCAGCAT 
 19,848,658  TTATAACTAT TGTCCATAGT TTCAAAAACT AGGTTGTCTT TCTCTTCTCA 
 19,848,708  CCAAGTTTGG GATTAACTAT GAAGAACCAA AGTGAACCCT TTCAACAACA 
 19,848,758  AGGTTTGCTG TGGTTTTCAA GTTTTGCCTT TGTGTGGAAC ATTGTAATGA 
 19,848,808  CATAGTGGGA AAAGAAATAT TTGGGGAGAG AATTAACCAT GGCTGATACA 
 19,848,858  TAGCACGGGT ATTTCTGAAC AACCTACTAA ATTATTTCTT AGAACATTTT rs73601656;p.9015/rs28445964-[A/G]; 
p.9024-[T/C] 
 19,848,908  GAAGTATATC TTGCCATAGG AGTGGGAACA GTTTCATACA AAAGCCTCCT 
 19,848,958  CATGCTTCCA ACTTTTCTTT AAAAAATTTT TTTTAAATTA TTTTATTAAA p.9130/rs13252357-[T/A] 
 19,849,008  AATAGAGGCC CGGCCCGATG GCTCACACTG GTAATCCCAG CACTTTAGGA 
 19,849,058  GGCTGAGGTG GGCAAATCAC TTGAGGCCAG GAGTTTGAGA ACAGCCTGGC 
 19,849,108  CAACATGGTG AAACCTCATC TCTACTAAAA ATCCAAAAAT TAACCAGGCC 
 19,849,158  CGGTGGCTCA TGCCTGTAAT CCCAGCATTT TAAGAGGCTG AGGCGGGTGG 
 19,849,208  ATCACTTGAG CCCAGGAGAT AGCGACCACC CTGGGCAACA TGGCCAAACT 
 19,849,258  TCATCTCTAC AAGAAATACA AGTTAGCCTG GCGTGGTGGC ACGCACCTGT p.9411/rs28689946-
[A/C];p.9418/rs28582042-[G/A] 
 19,849,308  GGTCCCAGCT ACTCAGGAAG CTGAGGTGGG AGGATCACTT GAGTTCGAGG 
 19,849,358  GTGCAGTGAA CCAAGATCGC ACCACTGCAC TCCTTTGGCC TGGGACACAG 
 19,849,408  AACAAGACCC TGTCTCAAAA AACAAAACAA AACAAAACAA CCCCCCCCCC p.9589-[C/T] 
 19,849,458  GCCCCACACA CACACAAATA GTGGAACTAT AGCACACAAG AGCCATGCAT 
 19,849,508  GAGTCAGTGT TCTCCACGAA AGCAAGCTTC AAAGTGGAAC TGAGAGACCG p.9696/rs73667468-[G/T] 
 19,849,558  GGCTCTGATC CTCACCCTCC CACTAATACC AGGGTAGCCT CAGCCAAGTC 
 19,849,608  ACTTAAATTC ATGTCTTGAG AGAAGACAGA ATTAACTAAG GAATCCCCAA 
 19,849,658  ACAGCAGTTC CCTTAGTTGA AATCACAAAC GTACACACAC ATACCCTGAC 
 19,849,708  TAAGGAGAGC TTCAAGAAAG GCTGGAAGAC TTAGGAGAGG TCAATGGTGA 
 19,849,758  CAATCTTAAT TCAGAGTTAA GGTTGTCTCT CTGTCAACTT TGCTCAACGT p.9914/rs73667469-[T/G] 
 19,849,808  TGGAGCATCT GTTGTTCTCT TGCAATCCAC ATTCGTTTTC GAAAACACTT 
 19,849,858  CAGAAACAAA AATAGCATCA GCGGTGGTTG CCTGTGAACC TAAAACATAT 
 19,849,908  CATTCCAATG AATAAAATCA AGCAACCCTC CAGTTAACCT CATATCCAAT 
 19,849,958  TTTTCCTTTC CAGAAAGAAG AGATTTTATC GACATCGAAA GTAAATTTGC Exon 2 p.10127/rs1801177-[G/A] 
  39 
 19,850,008  CCTAAGGACC CCTGAAGACA CAGCTGAGGA CACTTGCCAC CTCATTCCCG 
 19,850,058  GAGTAGCAGA GTCCGTGGCT ACCTGTCATT TCAATCACAG CAGCAAAACC rs11542065 
 19,850,108  TTCATGGTGA TCCATGGCTG GACGGTAAGG GAGGCTCTTT GGGGAAGAGT Intron 2 
 19,850,158  GGATTGGGGT GGTGAGGTAT CCTGACTGGC CTGCCCAATT GTTGGGGACC 
 19,850,208  CAGTGATGGG TCCGCACCCC ACATCTCACG TGGATCTCCT TACACTTGAA rs59054859 rs11570898 
 19,850,258  TAAAGACAGT TCTGGCTCAG GTGGGATCTG AAGCCACAGG TTCATGAGAA 
 19,850,308  CTCCCCCTAG GCAGTGCCAG CCTTCATTTT AACACTGTAC CTGGTTGGTG 
 19,850,358  CCCTTGAGCC AGAGCTTCCT GCGAGGTTGG TAAAGGATGC TCTGCCCAGC 
 19,850,408  TACTGAGCAG AAGATAGGTG ATTGCTGTGG GGAACCGGTG GAACCCTGGC 
 19,850,458  ATGATCCCGC ATCACCCAGC ACATTGCCAG GAGAACCTTT CTAAAGAAGA p.10632-[C/T] 
 19,850,508  CAGCATGGAA GAGTGAGGAG AGGGCTGGAG TGGAGTGAGG AAGTGTGGCG 
 19,850,558  TCCATGCTGG CTTTGCCATT CTCCAGCTCT GTGCTGTGGA TCAAGTCACT 
 19,850,608  TGTCATCTCT GGGCCTCCAT TTACTGATCT GTAAAGCAGA GGTTGCACTA 
 19,850,658  GATGTCCCTA AAAACACTCT ACTTCCAAAA TTTTCCAGTT GTAAACTTTA rs6991305 
 19,850,708  GGGAGCCTTT CTGGAAATTA AAAAAAAAAA GGGCTGGGCA GGGAACTGAC 
 19,850,758  ATGCTGACAT GCCAGATGAT TAGAAAAAGT GAAACTGTGA TTAAATTTAC p.10912-[A/G] 
 19,850,808  TTTAAAAAAT TGTTAAAAGT CCCCTCTCTA ATATGTCACA CAGTCACTTT p.10987-[C/A] 
 19,850,858  AGATTATGTA GTTCTTGCTT AGTTTGTTTT AAAATGTTTC AATCCCAAGT 
 19,850,908  GAGTAGACTG TGTAATTTAT TTAAAAGGAT TTGTGTAAAA TGGCTTGTTA p.11050/rs7016529-[T/C]; 
p.11090/rs8176337-[C/G] 
 19,850,958  AAGATATATT ATCTATCCAT TATGTCAGAG CTTGTGAATA TTATAATACT 
 19,851,008  AATTTCTAGT GAGAACTAAC TAAAAATAAC ATTCATCTAG TCCACATTTC 
 19,851,058  TTTTCCTACA TAATTTAAGT GGCTTTGTTA TTGACTGAAG AGGACAATCG p.11228-[T/C] 
 
 19,851,108  CTACAATTTT TATAGAGATG AGACTACTAC TAACAGAATT CACACAGATG 
 19,851,158  TTTAACAAAA TATAGCCATT TACTATGTTA ACATAGTAAA TTCAATATTT 
 19,851,208  TGTGATAAAA TCTCAAATTC CTAAACATAA ATCCTTTAAT ATTTTAATAG 
 19,851,258  GTGTAAGTAG GAAAAAGGAA TCTTTTTCTT TTTTGAGATG GAGGCTCACT 
 19,851,308  CTATTGCCCA GGCTGGAGTG CAGTGGCGCG ATCTCGGCTC ACTGCAACCT 
 19,851,358  CCGCCACCTG GGCATAAGAG ATTCTCCTGC CTCAGCCTCC CGAGTAGCTG 
 19,851,408  GGACTACAGG CGCCCACCAC CACACCCGGC CAATTTTTAT ATTTTCAGCA p.11574/rs34123038-[G/A] 
 19,851,458  CAGGCAGGGT TTCACCCTGT TGGCCAGGCT GGTCTCGAAC TCCTGACCTC p.11600-[G/C] 
 19,851,508  AAGTGATCTA CCCACCTTGG CCTCCCAAAG TGTTGGGATG ACAGGCGAGA 
 19,851,558  GCCACTGCAT CTGGCCCAGA AAAAGGAATC TTTAGAGGCC CTTTGGTTAT 
 19,851,608  ATACAGAACT TGGATTTTAA AATTTTTCAA AAAATCTGAG CTTAATAAAC p.11760/rs73667470-[A/C];rs60772381 
 19,851,658  GCATTTATAC AACAGAAATA AATTGAGTAT CTCAGTCATC TCAATCTTAT 
 19,851,708  CCCTGAGAGA ATTTTATACT TTGGGAAGTT GTGGGAAAAA AATGGTTCTT p.11888_11889-[InsA] 
 19,851,758  TTTCATACTA AGATGACATG ACCAACCCAA TATCAACAGA CGGTGCCACT 
 19,851,808  TCCTATCATT GGTCCTACTG CCTCACTAAG CCCACCTGTA TCTTTCACAT 
 19,851,858  CATGTGTCCT GACATTTTGA GTGCTTGAGC ACAGAGACTG CTGTCTGGCT 
 19,851,908  GTGGGACTGA GTTGGGTCTG TGCAAGAACT AAGCCAGCCA CACTGATCTT 
 19,851,958  GATTATCTCA GTGAACTCAC TGGCAGGGTC AGGTGGCCCA CCTGGTATAG 
 19,852,008  GCAGCAGGGA GGGCTTCAGT TCAGCTGCGT GTCTGAAAAC CAAAGATTTA 
 19,852,058  AAACATAGTA ATTATTGAAC CTCAGAAGAA AAACTCAGAT TGAAAGAACT p.12224_12920-[del697} 
 19,852,108  TAGAATAAGA CCCTTTTTGA GTTGAGAAAG GTGAGTACTT AGATTTTTCA 
 19,852,158  TTTGCTTTGT TTGGGATTAC TTACATCAGT ATTTTATGTT GATCAGAAAG 
 19,852,208  AAAGGATTCA ATTAGCTATT GTTCGGTTAA TAAAAATGTC AGCCACTGTA rs73667471 
 19,852,258  GGAGTAAGTT GGATGTCCAG CCTTTTTAGA TTGCTTAACT TGGAAACACT 
 19,852,308  GGGCTGGGAG CGGTGGCTCA TGCCTGTGAT CCCAGCACTC TGGGAGGCCA p.12449-[G>A];rs57357723;rs10095748 
;p.12484-[C/A] 
 19,852,358  AGGCAGGCAG ATCACTGGAG GTCAGGAGTT TGAGACCAAC CTGGCCAACA 
 19,852,408  TGGGGAAACC CAATCTCTAC TAAAAAAATA CAAAAAAATT AGCCAGGTGT p.12550-[G/A];rs58934202 
 19,852,458  GGTGGTATGT GCTTGTAGTC CCAGCTACTC AGGAGGCTGA GGCAGGAGAA 
 19,852,508  TCGCTTGAAC CAAGGAGGCG GAGGTTGCAC TGAGCTGAGA TCATGCCACT 
 19,852,558  GCACTCCAGC CTGGGCGAGA CAGTAAGACT CTGCCAAAAG AAAGGAAAGA 
 19,852,608  AAGGAGGGAA AGAAAGGAAG GAATGAAAGG AAGGAAGGGA AGGAGGAAGG 
 19,852,658  GAAGGAGGGA GGGAGGAAGG AAGGAAGGAA TGAAGGAAGG AAGGAAGGAA p.12810_12829-[dup20] 
 19,852,708  TGAAGGAAGG AAGGAAGGGA GGGAGGAAGA AAGGAAGGAA GAACAAAGAA p.12853_12854-{Ins16};p.12861_12864-
[del4];p.12878_12889-[del12]  
 19,852,758  AAGAGAAACA CTGGTAGTAC AGAAAAACTT CTGATAGAGG CCTAGAGTAA 
 19,852,808  ACCCGATTTT CTTGCCTTAT CTGAAATAAG CTGCCTGGGG ACTCACAGGC rs11570894 
 19,852,858  ACAGACGAAG GGAAATGAGG AGGCTCTCCA GCTGTGTCAT GAGACACCCA p.13003-[G/T] 
 19,852,908  AAGGAATGCT TAGCATGTAG CATGCATGTG ATACATCCCA GCAGGTTGCT 
 19,852,958  TAGACACAGC TATCTTGGAG CTTTGCCACT TGCTTGGATG TCACTGGCTT 
 19,853,008  TAAGTACAGG GTTCCCATTG TGAAGTAGGG GATCCTGGCT GAAACAGGGA rs7002728 
 19,853,058  GACATTAACA TTACATTCTG AAGAAATGAC ATCAACCTCT CCTGATCTTG 
 19,853,108  AAAGCCAACT ACAAAGGGTG CCCAACACCC CAACCTTGAA GGGAGGCGAA 
 19,853,158  GGTGAGTGGG ACTGGACCAA TTCAACAGGG TTCTGCTCCT AGCCAGGTGC 
 19,853,208  TCCTGCTAGT TTCCTCAAAG ACCCACTTTG CATTCAGACC AATCTTTCCT 
 19,853,258  TTTAATAGTA TAAATGATCA AAATTTTATT GAATGTCTAA AATATACTTT 
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 19,853,308  TTAAATGGGA AGCATGGTGA ACCCCAATCT GCCGTTCCTC AACTCAACTC 
 19,853,358  AATGCCTTCC TGGCTTACTT AGATCTGCCT TGGAAGGGAC AGACCTGTCT 
 19,853,408  CTGAACACTG TTCTGTTATT TGATTTTTCT ATCTGTGCCA ATGGGTTTCC 
 19,853,458  AATCAAGTTT GTTTTTTCCA TTTCATGCAG GTGTATTGGG CTGATGTATC p.13639-[G/A] 
 19,853,508  TATGACAAGT GGTAGGTGGG TATTTTAAGA AAGCTTGTGT CATCATCTTC 
 19,853,558  AGGTAACAGG AATGTATGAG AGTTGGGTGC CAAAACTTGT GGCCGCCCTG Exon 3 
 19,853,608  TACAAGAGAG AACCAGACTC CAATGTCATT GTGGTGGACT GGCTGTCACG 
 19,853,658  GGCTCAGGAG CATTACCCAG TGTCCGCGGG CTACACCAAA CTGGTGGGAC 
 19,853,708  AGGATGTGGC CCGGTTTATC AACTGGATGG AGGTAAGACT GGGAGAAGGA Intron 3 p.13854/rs1121923-[G/A]  
 19,853,758  GACTTATGTG TCCAAAACAG TGTTTTTGAC TGGAGCCAGA AAACCGGCTG rs3735959 
 19,853,808  TTCTTTCTTC CTTTTCTCTT AGATTTAAAT ATTTTCTGGG GGCATTCAAA 
 19,853,858  TCTTCAGAAT CAGCGTGGAT ATTATTTTAT ATCCAAAAGC AACATTTTGA 
 19,853,908  TAAGAATAGA CTATAAGGCC AATAAATAGT CCTGCCCTGC TCTATCGTTT 
 19,853,958  GATATTTTCA CAGTGAATAG ATCTGCTGAG ACCAATAACT AAGTGGGCCC p.14114/rs73667472-[T/C] 
 19,854,008  AACAGAAAAA AGCTTGTGAT TTTCGGACAG AGGAAAGATG GCATGTTCAG 
 19,854,058  CCAGACCCTT CCCTACCAGT TGGCTGGCCT GTGGACATCT TATCCTCACC rs58670071 
 19,854,108  TTGACATACC AATCTCTTTC ATGAAAATAT TAATAGTACT TATTCTTTAG 
 19,854,158  TGTGAAATAG GATGAACGTT TTTGTTGAGC ATTGGGAGAG TGATGGAATT 
 19,854,208  GAGCTAGGAA GATGTTGGAA GGGAAGGTGC ATAGGATAGA AGGGAACTGA 
 19,854,258  GGTCTGGAGT TCTGACTTAG CTGCAAGAGA CCCACTTTTT CACACGATCC 
 19,854,308  CTTGAGAAGT ACCTCTGAAA AGTATCTTGG GGTTGGAAAG AAGCTGATAC 
 19,854,358  TCTGACCAAG GCAAATTATT TTAACCAGGT AATTGGAAGT AAAAAATAAG 
 19,854,408  CTGTGTTTAT TAGACTGATC ATAAAAGACA AAAGTTCTTT TCTTGTCTTT 
 19,854,458  TTTGCTGACC AGGCAAATGA ACATGGGCAA ACGGGATCAC CTCCCTGGGG rs8176338 
 19,854,508  CTCAGGCTTC TCACCTGTTA AATGAGGGGC TGGACCATGT ACCTCTGGTC 
 19,854,558  CCTTCCACTG AATGTTTCCT GAGTCTGTCA TTGCTTGGCT AACCTTCAAT 
 19,854,608  GATAAAGTGA TACAGATATT TAGAGTAAGG AATAATGGGA AAATATATAC 
 19,854,658  CCATATACTA TACATTCAAA CATACACACA TATACATATA TGCATGCATA 
 19,854,708  TAAATGTATA CGCATATGTA TATGTGTATA TGTTTGTACG TATAGTATAT 
 19,854,758  GGTTATATAT GCAAATACAT ATACATATAC AAACATATGC ATATATTATA 
 19,854,808  TACATAAATA ATACTATTTC AGATGCATGG AAAAACTTTG TAATTTAAAT 
 19,854,858  CTGCTATTAA AGAAAGAGAA AATCAATTCT GGATTTGTTT ACGGAAAAGT 
 19,854,908  GAAACAAAAG AAAAAGACAA TTTTAACACT AGAGAATATT TTCTCTCTCT 
 19,854,958  TACCTGTAAC ACAAAATTAA AATAAGTAGA ATTAGTTTTC AGTATTTCCT rs57345602 
 19,855,008  ATATTTGGAA AACAATATTT ATATTCATTT TGTTTCTTTT AGTTTTATTT 
 19,855,058  TTGGCAGAAC TGTAAGCACC TTCATTTTCT TTTTCTTCCA AAGGAGGAGT Exon 4 p.15206/rs343-[C/A];rs247; 
rs11570897;p.15245/rs248-[G/A] 
 19,855,108  TTAACTACCC TCTGGACAAT GTCCATCTCT TGGGATACAG CCTTGGAGCC 
 19,855,158  CATGCTGCTG GCATTGCAGG AAGTCTGACC AATAAGAAAG TCAACAGAAT 
 19,855,208  TACTGGTAAG AAAGCAATTT CGTTGGTCTT ATCATAAGAG GTGAAAAGAC Intron 4 
 19,855,258  TGTCATTCTG AGAGAGAATC AGAACAAATT TTGTTAAATA CCCACATGTG p.15425/rs249-[T/C]  
 19,855,308  TGGTGTTCTT CCCGGAGACA TGACCAGCAC TTGATTATCT CATTGTAGGG p.15449_15450-[InsTG] 
 19,855,358  CTCTTTATTA GGGATAAGAA AAAACACAGA CGCTCTCACT GGCTTACTAT 
 19,855,408  CCACTGGCAA TAGCACAGAA ATAAAGCATA ATTACACACA ATGCCTGCAG rs251 
 19,855,458  ATTTCTCTGG GAAGCCTGTT TCCTCCCACT CTCAGCTCTG TGTTTTAGTA 
 19,855,508  GTGTAAATGC ACATCAGTAC TAGGAGAAAA GAAGAAGGAC CAATTCCAGA p.15653-[delA] 
 19,855,558  GGCCACTTCG AAAGAAGACC GTCATCTAGG CAAAGGTGTG GCATACACAC 
 19,855,608  AGAGAGAAAG AACCCACCAC TGTTTATACA TCTTCTCGAC ATATTCAGAA 
 19,855,658  ATAATCTACA AAAGGAAATC CAGCCATCCT GAGTGGAAAC TGCTGCATAA p.15836/rs253-[C/T] 
 19,855,708  GGCTAGTTTA AGAGACTCAA ATTCATTTTA GAAGGAGCCA AGCCTCCTTT 
 19,855,758  TATGTCTCTC TAAGTAAAGA TACCATGACT GTAGAATAGG AGCTAATAAG rs11570899 
 19,855,808  AATCTAAATA GCTGCCAGTG CATTCAAATG ATGAGCAGTG ACATGCGAAT 
 19,855,858  GTCATACGAA TGGAAATTTA CAAATCTGTG TTCCTGCTTT TTTCCCTTTT 
 19,855,908  AAGGCCTCGA TCCAGCTGGA CCTAACTTTG AGTATGCAGA AGCCCCGAGT Exon 5 
 19,855,958  CGTCTTTCTC CTGATGATGC AGATTTTGTA GACGTCTTAC ACACATTCAC 
 19,856,008  CAGAGGGTCC CCTGGTCGAA GCATTGGAAT CCAGAAACCA GTTGGGCATG rs45607438 
 19,856,058  TTGACATTTA CCCGAATGGA GGTACTTTTC AGCCAGGATG TAACATTGGA 
 19,856,108  GAAGCTATCC GCGTGATTGC AGAGAGAGGA CTTGGAGGTA AATATTATTT Intron 5 
 19,856,158  AGAAGCGAAT TAAATGTGAC TCTTATCCTT AACCCTTATT GACCCAATGT p.16316/rs254-[C/G];p.16320/rs255-
[T/C] 
 19,856,208  CCTACTCAGT AGCTTCAAAG TATGTAGTTT TCATATACAC ATTTGGCCAA p.16386/rs256-[C/T] 
 19,856,258  ATTATGTTTC TGAAGAATTC TGCAATGTTC AGCATGACCA CCTTAGAGCC p.16442-[G/C] 
 19,856,308  AGGCAGACAG CCATTTTATC TTTTATTTAC TATACTGTAG GCTACACTGA 
 19,856,358  GCAGTGCACT TACAGTAGCA AGAGAAAAAG GTGGGATTTT AGACAGGAAG 
 19,856,408  ACTCCACTGA CCTCAATAAT GGCATCATAA AATGCTATCT GGCCACATGT p.16563-[T/A] 
 19,856,458  TGTCATACCT TGAATGTAGC TGCAAAGCCA ATGGAAAGAT TTTAGATGTT 
 19,856,508  ACTGGAACAG AAGATGTTAA TTAGGATAAA TCTTCCAAAA TGTTCAGAAC rs257;p.16671/rs258-[G/C]; 
 19,856,558  ATAATGTTAG CTTAATGTTT TACTTTAATA ATGTTAGCTT GTGTTAAATT 
 19,856,608  TATGATTTTT GTTTGTTTGT TTTTTGAGAT AGAGTCTTAT TCTATTGCCC 
 19,856,658  AAGCTGGGGT GCAGTCACAC AATCACAGGG ACTTGCAATG TTGCCCAGGC 
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 19,856,708  TGGTCTCAAA CTCCTGGCCT CAAGTGATCC TCCTGCCTCA GCCTCCCAAA rs259 
 19,856,758  GTTCTGGGAT TGCAGCTGTG AGCCACCACG CCCAGTTTAC GATTTATTTT rs260 
 19,856,808  TAAGAGCCCC TTGCATACTT TATAGACATT GGGACCTACC TAGGATATTC 
 19,856,858  TCGTTATTTT TGTGCACGTA ATAGAACTTA GAGCATATTG TTACTATTTT rs261 
 19,856,908  CGATTGTCCT AAAAACTTAC AAGGAATTCA TTCTTATGGC ATTGCTGATT rs262 
 19,856,958  ATTTCTATGT TCATTTGATA TAAAAGAGTG TTAGTAGGGG CAGAACCCTC 
 19,857,008  AATTGTACAT AATATCAATG ATAAAATACA ATTCATTTAA CAATTACCCT 
 19,857,058  CTTAAGATGT GGTTTCTAGA AATACAAATT GTCCCTAACT TACAGTTTTC p.2713/rs263-[C/T] 
 19,857,108  CAACTTTACA ATTGGGCTGT AACACCATTT TAAGTTGAGA AGCACGTGAT rs9282782 
 19,857,158  GGTTTGACTT AAAACTTTTT GACATTATGA TGGGTTTTGG GGGTATTAAG 
 19,857,208  TGCATTTTGA CTTACAGTAT TTTTGACTTA TGAAGAATTT ATTGTAAGGC 
 19,857,258  AAGGGGCAGG TATATGTTTC TAGAAGCACC TAGAAGTGTT AGACACTTTC 
 19,857,308  AATGTAAGAG AAGGATGAGA TAAACAAGGA AATCAACCTC CACCTTGGAG p.17476-[A/C] 
 19,857,358  GCTTATTACA GCTTCATAAA CATACTCATA AATATAAGAA GCACAAAAGT 
 19,857,408  CAAAAATTCC CTGTGAACTT GCAACTTTCA CTCTCTTGAA GGTGGGTGGG 
 19,857,458  CCGCTACCAC CAAGAATATC TCCTGAAATA GGGCCTACAA TCATAAATGC p.17599/rs264-[G/A] 
 19,857,508  ACAGGACTAT ATCCTTGGGT GATTCTACTC TAACACCACA TCTCACCTAT rs265 
 19,857,558  TTTAGACATG CCAAATGAAA CACTCTTTGT GAATTTCTGC CGAGATACAA rs266;rs267 
 19,857,608  TCTTGGTGTC TCTTTTTTAC CCAGATGTGG ACCAGCTAGT GAAGTGCTCC Exon 6 
 19,857,658  CACGAGCGCT CCATTCATCT CTTCATCGAC TCTCTGTTGA ATGAAGAAAA rs28934893;rs35414700 
 19,857,708  TCCAAGTAAG GCCTACAGGT GCAGTTCCAA GGAAGCCTTT GAGAAAGGGC rs1800011 
 19,857,758  TCTGCTTGAG TTGTAGAAAG AACCGCTGCA ACAATCTGGG CTATGAGATC 
 19,857,808  AATAAAGTCA GAGCCAAAAG AAGCAGCAAA ATGTACCTGA AGACTCGTTC p.17948/rs268-[A/G] 
 19,857,858  TCAGATGCCC TACAAAGGTA GGCTGGAGAC TGTTGTAAAT AAGGAAACCA Intron 6 rs59184895 
 19,857,908  AGGAGTCCTA TTTCATCATG CTCACTGCAT CACATGTACT GATTCTGTCC p.18065-[T/G];p.18086/rs269-[T/G]; 
rs2075651; p.18095/rs270-[C/A] 
 19,857,958  ATTGGAACAG AGATGATGAC TGGTGTTACT AAACCCTGAG CCCTGGTGTT p.18121/rs271-[G/A] 
 19,858,008  TCTGTTGATA GGGGGTTGCA TTGATCCATT TGTCTGAGGC TTCTAATTCC 
 19,858,058  CATTGTCAGC AAGGTCCCAG TGCTCAGTGT GGGATTTGCA GCCTTGCTCG 
 19,858,108  CTGCCCTCCC CTGTAAATGT GGCCATTAGC ATGGGCTAGG CTATCAGCAC 
 19,858,158  AGAGCTCAGA GCTCATTTGG AACCATCCAC CTCGGGTCAA CAAACTATAA p.18297-[A/C] 
 19,858,208  CCCTTGTGCC AAATCCAGCC TACTTCCTGC TTTTGTAAAT AGTTTTTTTA rs272;p.18395_18396-[InsT] 
 19,858,258  AAACTTTTAA GTTCAGGGGT ACGTATGTAG GTTTGCTAAA AAGGTAAACT 
 19,858,308  TGTGACATGG GAGTTTGTTG TCCAGAATAT TCCATCACCC AGGTATTAAG p.18462-[T/G] 
 19,858,358  CTTAGTACCC ATTAGTTACT TTTCCTGAAG CTCTCCCTCC TCCCACCCTC 
 19,858,408  TGGGAGGCCC CAGTGTCTGT TGTTCCCCTC TATGTGCTCA TGCAAAGTTT 
 19,858,458  TATTAGGACA CAGCCACACA CATTCATTAC CATATTGTCA AAGGCTGGTT p.18621-[C/T] 
 19,858,508  TCATGCCACC ATAACAGAGT TGATAGCCCA CAGAGCCTAA AATATTTACT rs275 
 19,858,558  CCCTGGCCCT TTACAGAATG TTCACAACTT ACATAAAGGC AAGGACCATC p.18708/rs276-[T/C] 
 19,858,608  TGTCTTATTT ATTTATTTAT TTAATTTGAG ATGAAGTCTA GCTTTCTCCT 
 19,858,658  AGGCTGGAGG AGAGGGGCAT GATCTTGGCT CACCACAACC TCTGCCTCCC p.18822/rs277-[T/C] 
 19,858,708  GGGTTCAAAT GATTCCCCTG CCTCAGCCTC CGGAGTAGCT GGGATAACAG 
 19,858,758  GCATGCACCA TCATGCCCAG CTAATTTTTG TATTTTTAGT AGAGAGGGGG p.18942/rs278-[G/A] 
 19,858,808  TTTCACCGTG TTGACCAGGC TGGTCTCGAA CTGCTGACCT CAGGTGATCT 
 19,858,858  GCCCTCCTTG GCCTCATCTG TCTTTTTAAA TGCAACTATT CCTGGAAGGC 
 19,858,908  AAGAATATCT CACACCTTCT AAGATACTGC CATTTTGCCA GGAGTTTGTT 
 19,858,958  TCACACTTGA ATTTCAAGCT TGGCCTCTTG TTTAGAGGCA GACCTAAAGG rs279 
 19,859,008  AATGGTCGGA AAATGAGAGA GGAGGTCTTC GGATAAATCC GGTGAGAGGG 
 19,859,058  ACCAACTTCA GGAAGGGTGG CTTTTGTGGA ATCCAGATGG AAACCTGAGG 
 19,859,108  GAAGGGATGA TATTAAAGAA CAGTGGCCCC AGGTAAAACA TATGGCACCC 
 19,859,158  ATGTGTAAGG TGATTCTTAG AATCTGTAGA GGTGTCTTTC GTGGTATAGA rs280 
 19,859,208  GGTTGAGGCA CCTGTGCTTC AAGGAAACCT TAACTCTTCA AAATCAGGCA 
 19,859,258  ATGCGTATGA GGTAAAGAGA GGACTGTGGG ACCATAATCT TGAAGACACA rs17091775;p.19442/rs281-
[A/T];p.19445/rs282-[C/G] 
 19,859,308  GACAGGCTTC ACTCATCCCT GCCTCCTGCA CCAGTGGGTT CAAGGCTCTG 
 19,859,358  TCAGTGTCCC CTAGGGGCAC CTCACCACTC CCAGCTTCTT CAGCTCTGGC p.19517/rs283-[C/T];rs284 
 19,859,408  CTGTCCTGCT GCCTGCAAGG GTTTTGCTTA ATTCTCAATT CAATGTCTCT 
 19,859,458  TCATCTTTTA GCAGCTGTGG GGTTTTGTTG TTGTTCTTCT GTTTTTGCTT p.19608/rs285-[C/T] 
 19,859,508  AGTATCTGAC TACTTTTTAA TTATAAAAAG AGATGTATCT AAACAAAATA p.19675/rs286-[A/T] 
 19,859,558  GAGATTGTTA TCAGAAGTTC ACAACATTTA TTAAAAATTT TTTCACCTGG 
 19,859,608  ACAAGAGTCT AAAGCAGCAT AAAAATATGG TCTGCTATAT TCTAAACCAT 
 19,859,658  CAGTCTTAAG AGATCTGTGT CTCAGCTTAA GAGAAAATAC ATTTAATAGA p.19815-[G/A] 
 19,859,708  CAGTAACACA AATAAGAAAA AAATCTGACC AAGGATAGTG GGATATAGAA 
 19,859,758  GAAAAAACAT TCCAAGAATT ATTTTATTTA TTTATTTATT TATTTATTTA 
 19,859,808  TTTATTTATT TATTTATTTT TGAGACACAG TCTCGCTCAG TTACCCAGGC p.19975/rs287-[A/G] 
 19,859,858  TGGAGTGCAG CGGCGCAATC TTAGCTCACT GCAACCTCTG CTTTCCGGTT rs288;rs2583659;p.20038/rs289-[T/C] 
 19,859,908  CAAGCGATTC TCCTGCCTCA GCCTCCTGAG TAACTGGGAT TACAGGCACC p.20080-[C/T] 
 19,859,958  CGCCACCACG CCCAACTAAT TTCTGTATTT TTCTTAGTAG AAACAGGGTT rs34951282 
 19,860,008  TCACCATGTT GGCCAAGCTA GTCTCAAACT CCTGACCTCA GGTGATTCAC rs290 
 19,860,058  CCACCAAGGC CTCCCAAAGT GCTGGGATTA CAGGCATGAG CCACCATGCC 
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 19,860,108  TGGCCTCCAA GAACTCTTTT TTCCTCCATC ATCATGGTTC TATTTTAGTC rs2698206;p.20271/rs291-[T/C] 
 19,860,158  CTGCTGCCTT TCCTTTTAAC CTCTCCCCAG GCCCATTTGC TCAGGGTTTT 
 19,860,208  TGGTAGAGAC CAGAGGAGGG GCAGGGAGGA GATATAGAAG TTCAACTACC p.20363-[A/T] 
 19,860,258  TGCTTCCAGA GGCTGTCCCT AGTATAGAAT ACTTTAGGGG CTGGCTTTAC 
 19,860,308  AAGGCAGTCC TTGTGGCCTC ACTGATGGCT CAATGAAATA AGTTCTTTTT rs292 
 19,860,358  TAAAAAAAAT TTTATTTATT TCCATAGGTT ATTGGGGGAA CAGGTGGTGT p.20505_20506-[InsA];p.20544/rs294-
[T/C] 
 19,860,408  TTGGTTACAT GAGTAAGTTC TTTAGTAGTG ATTTGTGAGA TTTTGGTGTG 
 19,860,458  CCCATTACGG AATGGAAAAA TCAACGAAAT AAGTTCTATG ATGCACCTAC 
 19,860,508  TAGACACCTA ATCTGCGCTA GATGGTGGGG GAATTAAGAG CATGGGCATG p.20657/rs295-[A/C];p.20663/rs296-
[G/A] 
 19,860,558  ATCCTGTGAC CGGAAGCCCG CTTACAGTCA GGGTGGAGGA CAGACCTACT 
 19,860,608  CATGAAACAA ACACAGTGAC ATATAGTGAC ACAGAAGCAA ATGTCAAATA p.20790/rs297-[T/C] 
 19,860,658  TGCTTGCTCC AGATGCTAAG GCACAAGATG GCCAAGGATG GCGGAGTTCA 
 19,860,708  TGGAGAAAGC ATCATGAGTG TTTTGGCCTT CTGATTTGAT CTCCCTAGCA 
 19,860,758  CCCCTCAAAG ATGGCTACTT CCTAATGCTG CTTGGCAATT CAGACACATT 
 19,860,808  TGGGTTTTTC CTATGCATAT AACCACACTT TTCTGAAAGG GAGTAGAATT 
 19,860,858  CAAGGTCTGC ATTTTCTAGG TATGAACACT GTGCATGATG AAGTCTTTCC 
 19,860,908  AAGCCACACC AGTGGTTCCA TGTGTGTGCA CTTCCGGTTT GAGTGCTAGT 
 19,860,958  GAGATACTTC TGTGGTTCTG AATTGCCTGA CTATTTGGGG TTGTGATATT p.21125_21128-[delGACT];rs73601683 
 19,861,008  TTCATAAAGA TTGATCAACA TGTTCGAATT TCCTCCCCAA CAGTCTTCCA Exon 7 
 19,861,058  TTACCAAGTA AAGATTCATT TTTCTGGGAC TGAGAGTGAA ACCCATACCA 
 19,861,108  ATCAGGCCTT TGAGATTTCT CTGTATGGCA CCGTGGCCGA GAGTGAGAAC rs298 
 19,861,158  ATCCCATTCA CTCTGTGAGT AGCACAGGGG GGCGGTCATC ATGGCACCAG Intron 7 rs299 rs300  
 19,861,208  TCCCTCTCCT GCCATAACCC TTGGTCTGAG CAGCAGAAGC AGAGAGCGAT p.21353/rs301-[T/C];rs302;rs34500595 
 19,861,258  GCCTAGAAAA CAAGTCTTTA GTTAAAAAAA TCAGAATTTC AAAATTGAGG 
 19,861,308  TCTTTCCTCT ATTTGATATT GAGAAAAAAA TGCTTCAAAT TGGCCATTTT 
 19,861,358  ATTTTCACTT ACTAGTTATA TTTTTTTATT TATCATCTTA TATCTGTTTA 
 19,861,408  TTTCTTTTAT AAAGCTGCTG TTAAACAATA TAATTAAACT ATCTCAAAAG 
 19,861,458  GTTTGACATT AAAGAAAATG AGCAATGGTA ACAGGAAACC ACTCTATAGA 
 19,861,508  TGTACATATA ATATGTACAG AAAATATAAG TAGTAAGAAG TCCATGACAA 
 19,861,558  AGTGTTAGCT CTTTTTTTTT TTTTTTTTTT TTTTTTTTTT GAGATGGAGT rs303;rs13257355 
 19,861,608  CTCTCTCTAT TGCCCAGGCT GGAGTGCAGT GATTCGATCT CAGCTCACTG p.21780/rs304-[T/G] 
 19,861,658  CAACCTCTAC CTCCCGAGTT CAAACAATTC TTCTGTCTCA GCCTCCCGAG p.21820/rs305-[A/G] 
 19,861,708  TAGCTGGGGC TGCAGGTGCC CACCACCATG CCCAGCTAAT TTTTGTATTT rs306;rs307; p.21895/rs308-[T/G] 
 19,861,758  TTAGTAGCGA CAGGGTCTCA CCATGTTGGC CAAGCTGGTC TTGAATTCCT rs309 
 19,861,808  GATCTCAGGT GATCCACCCG CCTCGGCCTC CCAAAGTGCT GGGATTACAG p.21965/rs310-[C/T] 
 19,861,858  GTGTGAGCCA CCATGCCCAG CCTACCCTTT ACTACTAATC AAAGAAATAA p.22044_22047_[delTAAA] 
 19,861,908  AAGTAAGGCA ACTTGATACT TTTACAATTA CTAGATGAAC AAATCTTTAA 
 19,861,958  AAATAGCCAG TGCAGACAAG GTGGTGAAGC AGAACATGCG AACCTACCAT 
 19,862,008  GCATCATTCA CGGCTAGAAC CCTCCAGGTG CGGAAGGTAG TATTTTAATA 
 19,862,058  ACTTTCCATA GCTACAAAAT ATTATTACAT AGAAGGGAGT GATTTTTTTC 
 19,862,108  TAATATTTAT CCTAAAGAAA TAGTCAACAA ACATTTTTAA AAACATCAAT 
 19,862,158  TACAGTCGTA CCTATACTAG CATAAATTAG AAACCCAGTA TCCAACATTG 
 19,862,208  AGGCAGTGGG TAAATGAATC GTGGTTTATC AAGTCATTAA AATCAATCTA 
 19,862,258  GCCTTTAAAA ACTATAATTG TAGGAAACCC AGGAAAACAT AGTAAAAAAT p.22416/rs312-[G/C];rs313 
 19,862,308  GGAATATAAA ATCTGAAGAG AATAAAGAAT AGAGAATCGT ATGTGTGCTA p.22461/rs314-[G/A] 
 19,862,358  TGATTGTAGC TAAATAATGT TCAAGTATCA ACACAAATTG AAAAGGAATA p.22514/rs315-[T/C] 
 19,862,408  CATGAAAATG AAAATTATAT TTCTGAATGA TTGACTTCAG GATTTTCTTT 
 19,862,458  TAGAATTGTA TTAAATAGTT CATGTCATTA GGATAAATGC TGGAATGTGG 
 19,862,508  ATATAATTTA AAATATACTA AATGCCATCG ACCTTCATTT TGAGTTCTTT 
 19,862,558  GTTGGACATT TTTGTGCATT TTTAAAATAT CCCCTAAATA ATAAAGCTAT 
 19,862,608  TTATATTTGG AGAGGAGAAA AAAAAGTGGG GGGCAGGGAG AGCTGATCTC 
 19,862,658  TATAACTAAC CAAATTTATT GCTTTTTTGT TTAGGCCTGA AGTTTCCACA Exon 8 
 19,862,708  AATAAGACCT ACTCCTTCCT AATTTACACA GAGGTAGATA TTGGAGAACT p.22855/rs316-[C/A] 
 19,862,758  ACTCATGTTG AAGCTCAAAT GGAAGAGTGA TTCATACTTT AGCTGGTCAG 
 19,862,808  ACTGGTGGAG CAGTCCCGGC TTCGCCATTC AGAAGATCAG AGTAAAAGCA rs5934 
 19,862,858  GGAGAGACTC AGAAAAAGTA ATTAAATGTA TTTTTCTTCC TTCACTTTAG Intron 8 
 19,862,908  ACCCCCACCT GATGTCAGGA CCTAGGGGCT GTATTTCAGG GGCCTTCACA 
 19,862,958  ATTCAGGGAG AGCTTTAGGA AACCTTGTAT TTATTACTGT ATGATGTAGA 
 19,863,008  TTTTCTTTAG GAGTCTTCTT TTATTTTCTT ATTTTTGGGG GGCAGGGGGG p.23190_23191-[delAG];p23192-[G/T] 
 19,863,058  GGGAAGTGAC AGTATTTTTG TATTTCATGT AAGGAAAACA TAAGCCCTGA 
 19,863,108  ATCGCTCACA GTTATTCAGT GAGAGCTGGG ATTAGAAGTC AGGAATCTCA 
 19,863,158  GCTTCTCATT TGGCACTGTT TCTTGTAAGT ACAAAATAGT TAGGGAACAA 
 19,863,208  ACCTCCGAGA TGCTACCTGG ATAATCAAAG ATTCAAACCA ACCTCTTCAA p.23388/rs318-[C/G];p23395/rs319-[A/C] 
 19,863,258  GAAGGGTGAG ATTCCAAGAT AATCTCAACC TGTCTCCGCA GCCCCACCCA 
 19,863,308  TGTGTACCCA TAAAATGAAT TACACAGAGA TCGCTATAGG ATTTAAAGCT p.23496/rs320-[T/G] 
 19,863,358  TTTATACTAA ATGTGCTGGG ATTTTGCAAA CTATAGTGTG CTGTTATTGT 
 19,863,408  TAATTTAAAA AAACTCTAAG TTAGGATTGA CAAATTATTT CTCTTTAGTC p.23573-[T/C] 
 19,863,458  ATTTGCTTGT ATCACCAAAG AAGCAAACAA ACAAACAAAA AAAAAAAGAA rs321;p.23636/rs322-[A/C];rs323 
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 19,863,508  AAAGATCTTG GGGATGGAAA TGTTATAAAG AATCTTTTTT ACACTAGCAA 
 19,863,558  TGTCTAGCTG AAGGCAGATG CCCTAATTCC TTAATGCAGA TGCTAAGAGA 
 19,863,608  TGGCAGAGTT GATCTTTTAT CATCTCTTGG TGAAAGCCCA GTAACATAAG p.23747/rs325-[T/C] 
 19,863,658  ACTGCTCTAG GCTGTCTGCA TGCCTGTCTA TCTAAATTAA CTAGCTTGGT 
 19,863,708  TGCTGAACAC CAGGTTAGGC TCTCAAATTA CCCTCTGATT CTGATGTGGC p.23858/rs326-[A/G];rs7005541 
 19,863,758  CTGAGTGTGA CAGTTAATTA TTGGGAATAT CAAAACAATT ACCCAGCATG 
 19,863,808  ATCATGTATT ATTTAAACAG TCCTGACAGA ACTGTACCTT TGTGAACAGT p.23955/rs327-[T/G] 
 19,863,858  GCTTTTGATT GTTCTACATG GCATATTCAC ATCCATTTTC TTCCACAGGG Exon 9 
 19,863,908  TGATCTTCTG TTCTAGGGAG AAAGTGTCTC ATTTGCAGAA AGGAAAGGCA  
 19,863,958  CCTGCGGTAT TTGTGAAATG CCATGACAAG TCTCTGAATA AGAAGTCAGG p.24143/rs328-[C/G] 
 19,864,008  CTGGTGAGCA TTCTGGGCTA AAGCTGACTG GGCATCCTGA GCTTGCACCC Intron 9 
 19,864,058  TAAGGGAGGC AGCTTCATGC ATTCCTCTTC ACCCCATCAC CAGCAGCTTG 
 19,864,108  CCCTGACTCA TGTGATCAAA GCATTCAATC AGTCTTTCTT AGTCCTTCTG 
 19,864,158  CATATGTATC AAATGGGTCT GTTGCTTTAT GCAATACTTC CTCTTTTTTT 
 19,864,208  CTTTCTCCTC TTGTTTCTCC CAGCCCGGAC CTTCAACCCA GGCACACATT 
 19,864,258  TTAGGTTTTA TTTTACTCCT TGAACTACCC CTGAATCTTC ACTTCTCCTT 
 19,864,308  TTTTCTCTAC TGCGTCTCTG CTGACTTTGC AGATGCCATC TGCAGAGCAT 
 19,864,358  GTAACACAAG TTTAGTAGTT GCCGTTCTGG CTGTGGGTGC AGCTCTTCCC p.24505/rs329-[A/G] 
 19,864,408  AGGATGTATT CAGGGAAGTA AAAAGATCTC ACTGCATCAC CTGCAGCCAC p.24573-[T/C] 
 19,864,458  ATAGTTCTTG ATTCTCCAAG TGCCAGCATA CTCCGGGACA CACAGCCAAC 
 19,864,508  AGGGCTGCCC CAAGCACCCA TCTCAAAACC CTCAAAGCTG CCAAGCAAAC rs12544438 
 19,864,558  AGAATGAGAG TTATAGGAAA CTGTTCTCTC TTCTATCTCC AAACAACTCT 
 19,864,608  GTGCCTCTTT CCTACCTGAC CTTTAGGGCT AATCCATGTG GCAGCTGTTA 
 19,864,658  GCTGCATCTT TCCAGAGCGT CAGTACTGAG AGGACACTAA GCATGTGACC p.24815/rs330-[G/A;p.24824/rs331-[G/A] 
 19,864,708  TTCACTACTC CTGTTCTGAA TTCCAGGAAT ATGCCCTTTT CAACCCTCCA p.24852/rs12679834-[T/C] 
 19,864,758  CACATCCCCT GCCAGACAGC AAGTGCTAAT GGGTTACAGG AACAAAGGGG p.24899-[C/T] 
 19,864,808  AGAAATATTA GATCATGTCA TACAAGCCAG TGACACAAGA AATGAAGGGA 
 19,864,858  AAGGCTAGAC ACAGTGTCAT CTGGAAACAG GAAAAGCAAT TGCTTTTGGT p.25005-[A/G] 
 19,864,908  TTGTTCTTTT CCTAGTTTGC ATTTGGGACA AATGTATAGA ATAAGAATTG p.25049-[G/A];rs28681081 
 19,864,958  CCTTCATGCC TGCAATCCCA GCACTTTGGG AGGCTGAGGC AGGTGGATCA 
 19,865,008  CCTGAGGTCA GGAGTTTGAG ACCAGCCTGG CCAACGTGGC GAAACCACCT 
 19,865,058  CTCTACTAAA AATATAAAAA TTAGCTGGGT GTGGCGGCAC ATGCCTGTAA 
 19,865,108  TCCCAGCTAC TCGGCAGGCT GAGGCGGGAG AATTGCTTGA ACCGGGGAGG 
 19,865,158  CAGAGGTTGC AGTGAGATGA GATCGCGCCA TTATATTCCA GCCTGGGCAA p.25320-[C/T];p25335-[C/T] 
 19,865,208  CAGAGAAAGA CTCCATCTCA AAAAAAAAAA AAACATGCCT ATTAGGAAAA p.25352-[A/C];rs28578146 
 19,865,258  GTATATTAAA GACCCTATGT GTAACATCTT TAATGTTTTT AAATTCTACT rs28599962 
 19,865,308  TTATAATAGA TTTTATACAT GTTTACTATA AATAGATTAG GAAAAATAAG rs13261181 
 19,865,358  CAAAAATAAA ATAAAATCAC TGTGACCATA TCACTCAGAG ACAACCCCAA 
 19,865,408  TTAACGTTTT TATTTATATT CTTTCGGACT TTATATATAC ATAATATTTA 
 19,865,458  TATGTTTTTC GTCCTTTACA AAAATAGAAT TATGGTGTAT ATACTCTGAA 
 19,865,508  TGACTAGATG AGAACATCTG GATCAAAAGC ATTAATGTAA GAGCATTCAG rs17116619 rs28439839 
 19,865,558  GATAAACTCA AAATGGAGAA TAGTTAGTGG TATTGAGCCA GGCAAAATAA 
 19,865,608  CGCAATTCTT ATCTAACTGG AGACTTTTCT TCTAAGAGGT TATTACGTTG 
 19,865,658  TTTTTCCTCA TCACAAATCT GAGGCAATAT CATACTTTCT TCAGTTCTTA rs28424158;p25844-[T/G] 
 19,865,708  GAAAGAGACT TTTAGATGAA GTTTTTTTTG TTTGTTTTGG TTTTTTTTTT rs28716400 
 19,865,758  CTTGAGATGG AGTTTTGCTC TTGCTGCCCA GGCTGGAGTG TAGTGGCTCG 
 19,865,808  ATCTCAGCTC ACTGCAACCT CCACCTCCTG GGTTCAAGCA ATTCTCCTGC 
 19,865,858  CTCAGCCTCC CAAGTAGCTG GGATTACACG TGTCCGCCAC CACACCTGGC 
 19,865,908  TAATTTCGTA TTTTTAGTAG AGAAAGGGTT TCACCATGTT GGTCAGGCTG rs4416836 
 19,865,958  GTCTTGAACT CCTAACCTCA GGTTATCCAC CTGCCTCGGC CTCCCAAAGT 
 19,866,008  GCTGGGATTA TAGGTGTGAG TCACCACACC CGGCCCTAGA TGCAGTTTTA 
 19,866,058  TACATGCATT TGTATTACAC ATAAATAGCA TGCATATTCT GCCAGAGCAT p.26201-[T/G];p.26234/rs10099160-[T/G] 
 19,866,108  CTACAACTTT AAATCTACAT GTGAATGTGA AAATAAAACC TCATTAAATT 
 19,866,158  AGTAAATAAC TCTAGCTGCT TGTAAAGCAC GTCCAGTCGT ATTTTTTATA 
 19,866,208  TGTTACAAGA CTTTATCTGA GAAAGCCTAA TGAAGCATTC CTTGTCTGAT 
 19,866,258  TATAGGATTA CTGACAGAAC AGTTATTTAG ACAGAGAATG TTCAGATGCG 
 19,866,308  TTTTATTTTT ATTTTTTACT TTTATTTATT TTTGAGACAG TCTCGTTCTG 
 19,866,358  TTGCCCAGGC TAGAATGTGG TGGCGTGATC TCGGCTCAAT GCAACTCTGC 
 19,866,408  CTCCCGGGTT CAAGTGATTC TTGTGCCTCA GCCTGACAAG TAGCTGGGAT rs58844409 
 19,866,458  TATAGGTGCC CGTTACCATG CCCAGCTAAT TTTTCTGTTT TTAGTAGAGA 
 19,866,508  CGGAGTTTCA CCATATTGGC CAGGCTGGTC ATTGAACTCC TAACCTCAGG 
 19,866,558  TGATGTGCCT GTCTCAGCCT CCCAATGTGC TGGGATTACA GGCATGAGCC 
 19,866,608  ACAGCACCCA GCCAGATGCA TTTTTAAAAA CGTACCTGAA CTTTATCTAG 
 19,866,658  GAGGTAATTA TAAATTAGAC TAATAATCTT CTACAGTTTC TTTCTTCTGT 
 19,866,708  GATTAAAATC AATCAAATCA AAGATTCTCT TTCTCACACC TTCTGCTAAC 
 19,866,758  TCCTCAGAAA CCTCATATCA CAAGAAATGA AATGGAACAG GCCTTTCGTT 
 19,866,808  TGATACATTT TAGAATAAGA AATCCTCTAA ATTTAGAAGT CATTTGGCCC 
 19,866,858  AGTCCTCCAA AAATGATGCA CCTTATTGGG ACGGGGCTAA ATAGTTGCTC p.27000-[C/T] 
 19,866,908  CAGTGTCTTC CATTCCTACA AACCTGCCAT TCTCTGATCC ATTATACACA 
 19,866,958  TCTCCCCTGG GTTTATTCTC ACAACCTTTG TTCTGAAATT CCATTTGAAG rs10283151 
  44 
 19,867,008  GCTTTTTCCA TCCTAAAACC AGTGGGGGAC AGGCGGGAAT TGTAAAACAC p.27160-[T/A] 
 19,867,058  TCAGAAGATA ATAAATTGCC CTTTTTCCTG TGCTTTTTCT CAGAaactgg Exon 10 p.27229/rs11570891-[C/T]  
 19,867,108  gcgaatctac agaacaaaga acggcatgtg aattctgtga agaatgaagt p.27249/rs4922115-[G/A];rs7818177 
 19,867,158  ggaggaagta acttttacaa aacataccca gtgtttgggg tgtttcaaaa 
 19,867,208  gtggattttc ctgaatatta atcccagccc tacccttgtt agttatttta 
 19,867,258  ggagacagtc tcaagcacta aaaagtggct aattcaattt atggggtata 
 19,867,308  gtggccaaat agcacatcct ccaacgttaa aagacagtgg atcatgaaaa 
 19,867,358  gtgctgtttt gtcctttgag aaagaaataa ttgtttgagc gcagagtaaa 
 19,867,408  ataaggctcc ttcatgtggc gtattgggcc atagcctata attggttaga 
 19,867,458  acctcctatt ttaattggaa ttctggatct ttcggactga ggccttctca p.27611/rs3289-[T/C] 
 19,867,508  aactttactc taagtctcca agaatacaga aaatgctttt ccgcggcacg p.27688-[C/T] 
 19,867,558  aatcagactc atctacacag cagtatgaat gatgttttag aatgattccc 
 19,867,608  tcttgctatt ggaatgtggt ccagacgtca accaggaaca tgtaacttgg p.27783-[A/T] 
 19,867,658  agagggacga agaaagggtc tgataaacac agaggtttta aacagtccct rs11542064 
 19,867,708  accattggcc tgcatcatga caaagttaca aattcaagga gatataaaat 
 19,867,758  ctagatcaat taattcttaa taggctttat cgtttattgc ttaatccctc 
 19,867,808  tctccccctt cttttttgtc tcaagattat attataataa tgttctctgg 
 19,867,858  gtaggtgttg aaaatgagcc tgtaatcctc agctgacaca taatttgaat p.28036/rs11570892-[A/G] 
 19,867,908  ggtgcagaaa aaaaaaaaga aaccgtaatt ttattattag attctccaaa rs1059497;p.28067/rs3208305-[A/T]; 
rs11570896;p.28093/rs1803924-[C/T] 
 19,867,958  tgattttcat caatttaaaa tcattcaata tctgacagtt actcttcagt 
 19,868,008  tttaggctta ccttggtcat gcttcagttg tacttccagt gcgtctcttt rs11570893 
 19,868,058  tgttcctggc tttgacatga aaagataggt ttgagttcaa attttgcatt 
 19,868,108  gtgtgagctt ctacagattt tagacaagga ccgtttttac taagtaaaag 
 19,868,158  ggtggagagg ttcctggggt ggattcctaa gcagtgcttg taaaccatcg 
 19,868,208  cgtgcaatga gccagatgga gtaccatgag ggttgctatt tgttgttttt p.28382/rs1059507-[C/T] 
 19,868,258  aacaactaat caagagtgag tgaacaacta tttataaact agatctccta p.28407-[C/A] 
 19,868,308  tttttcagaa tgctcttcta cgtataaata tgaaatgata aagatgtcaa p.28464/rs3735964-
[C/A];p.28490/rs3200218-[A/G] 
 19,868,358  atatctcaga ggctatagct gggaacccga ctgtgaaagt atgtgatatc p.28524-[C/T] 
 19,868,408  tgaacacata ctagaaagct ctgcatgtgt gttgtccttc agcataattc 
 19,868,458  ggaagggaaa acagtcgatc aagggatgta ttggaacatg tcggagtaga rs1803923 
 19,868,508  aattgttcct gatgtgccag aacttcgacc ctttctctga gagagatgat rs58998793 
 19,868,558  cgtgcctata aatagtagga ccaatgttgt gattaacatc atcaggcttg 
 19,868,608  gaatgaattc tctctaaaaa taaaatgatg tatgatttgt tgttggcatc 
 19,868,658  ccctttatta attcattaaa tttctggatt tgggttgtga cccagggtgc 
 19,868,708  attaacttaa aagattcact aaagcagcac atagcactgg gaactctggc 
 19,868,758  tccgaaaaac tttgttatat atatcaagga tgttctggct ttacatttta p.28911/rs13702-[T/C] 
 19,868,808  tttattagct gtaaatacat gtgtggatgt gtaaatggag cttgtacata p.28982/rs1059611-[T/C] 
 19,868,858  ttggaaaggt cattgtggct atctgcattt ataaatgtgt ggtgctaact rs17091815;p.29046_29047-[InsTT] 
 19,868,908  gtatgtgtct ttatcagtga tggtctcaca gagccaactc actcttatga p.29086/rs15285-
[C/T];p.29088/rs3866471-[C/A] 
 19,868,958  aatgggcttt aacaaaacaa gaaagaaacg tacttaactg tgtgaagaaa 
 19,869,008  tggaatcagc ttttaataaa attgacaaca ttttattacc aca 
 19,869,051  ctaagtcatt attttgtatc atttttaaag taaatttatt cttaggtcag rs71510671 
 19,869,101  attcactcag catattttga ctaagtaacc actgtactta gtaaaccgaa p.29287/rs3916027-[G/A] 
 19,869,151  gagcttctga gaattatagt gtaccttata gatattttta acatttatat p.29315/rs9644636-[T/G] 
 19,869,201  ttgtataaag ctaaagaaag ccttacatat cctttaaact gactatagaa 
 19,869,251  gaaaatgata cagaattttg cctgcataaa gtacacagga ctattcttgc 
 19,869,301  ctacaatatg ctttttcaca agcaaaatgt tagactaata taaggcatct p.29474-[C/T];p.29487/rs4921683-[T/A] 
 19,869,351  ttggccattt tatagtgtac atcatctcta tttctgaggc ctcattgtta 
 19,869,401  gctgtaacgc aagtagcatt tgtgcaataa aatgaactat ttgggatggg p.29547/rs4921684-[C/T];p.29557_29558-
[InsA] 
 19,869,451  agggtacatt ttttagaact ttgctttggg ttgccttgat aattaatagc 
 19,869,501  atatagtcca tttatgcagc taagtaggga ttgcttctta gtacagtcag 
 19,869,551  gaagaattta gcccagaaaa caattatttc aatggccact gacccaaact p.29716-[T/C] 
 19,869,601  tccaggctga agagcaatgg cgtgatcatg gctcactgca cctccacctc 
 19,869,651  ccaggctcaa gtgattctcc tgcctcagcc tcccaagtag atggtactac 
 19,869,701  aagcacacgc cactgcaccc agctaatttt tgtatttttt gtagagatgg 
 19,869,751  gggtttcacc atgttgccca ggctggtctt aaattcctgg cctcaagtgt 
 19,869,801  ctgcccccct tggcctccca aagtgctgga attacaggca tgagccacca 
 19,869,851  tgtccagcct tgacccaaac ttttattgtc agttagctat tggggcttct 
 19,869,901  ggagtttggg tctcccctga caggaggggg ctccccagtt cacacttggc 
 19,869,951  cactgcccat caattcctgt tgatatgatc aacaagatag acaattgcaa 
 19,870,001  atgttgctga ggatgtggag aagtgtgaac ctgtgtaagt ggctgatggg 
 
Figure 4. LPL Annotated Sequence 
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3.2   DISTRIBUTION OF LPL VARIANTS IN HIGH AND LOW HDL-C GROUPS 
Of the 178 identified variants (excluding microsatellite), 88 had MAF ≥0.05 and 9 1 had a 
MAF<0.05. The MAF range for the 74 variants which have not been previously identified in the 
dbSNP build 130 was 0.005-0.500%. Among common variants, 32 had a statistically significant 
difference (P-value<0.05) when comparing the allele frequencies between the high HDL-C and 
low HDL-C groups; the P-value range was 0.048-0.002. Figure 6 shows the LD pattern of these 
significant variants in Section 3.3. In addition to 32 variants, 5 of the common variants have a P-
value of between 0.05 and 0.10. 
Of the 91 relatively uncommon or rare variants (MAF<0.05), 21 were present only in the 
low HDL-C group and 25 were present only in the high HDL-C group and the remaining were 
present in both groups. Forty of 47 (85.1%)  individuals with high HDL-C had minimum one rare 
variant versus 35 out of 48 (72.9%) individuals with low HDL-C; 23 of 47 (72.9%) individuals 
high HDL-C had minimum two rare variants versus 16 out of 48 (33.3%) individuals with low 
HDL-C; 17 of 47 (36.1%) individuals with high HDL-C had minimum three rare variants versus 8 
out of 48 (16.6%) individuals with low HDL-C. There were some individuals that had low 
genotyping call rates so it is worth mentioning that they may be underestimated in the analysis of 
rare variants.  
Among 23 identified exonic variants, 10 were relatively uncommon or rare variants (MAF 
<0.05). Of these 10 relatively uncommon or rare exonic variants, two were found only in the high 
HDL-C group (24143C>G, Ser447X) and (27783A>T, P=0.142) which are located in exon 9 and 
untranslated region of the exon 10, respectively. On the other hand, two were found only in low 
HDL-C group (27688C>T, P=0.326 and 28524C>T, P=0.321), however, they are located in the 
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untranslated region of exon 10. There was a one base insertion in the 3’ flanking region which 
was found only in the low HDL-C group (29557_29558InsA, P=0.321) but the remaining 19 
exonic variants were found in both the high and low HDL-groups. Table 9 summarizes the 
distribution of common LPL variants in high and low HDL-C groups. The relatively uncommon 
or rare LPL variants in high and low HDL-C groups are listed in Table 10 and the variants which 
were found only in high or low HDL-C groups are specifically highlighted; the 25 variants that 
were found in only high HDL-C group are highlighted in yellow and the 21 variants that were 
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Table 10.Distribution of common LPL variants in high and low HDL-C groups in NHWs 
LPL variant 






Low HDL-C P value 
2335 G>T Intron 1 rs3779787 0.122 T 0.163 0.083 0.096 
3558 G>A Intron 1 rs34309063 0.247 A 0.160 0.333 0.006 
3964 G>C Intron 1 rs17410577 0.239 C 0.160 0.320 0.010 
4060 G>T Intron 1 rs1534649 0.430 T 0.383 0.478 0.189 
4424 A>G Intron 1 rs13266204 0.263 G 0.200 0.330 0.038 
5949 T>G Intron 1  0.137 G 0.160 0.115 0.367 
6821 C>T Intron 1 rs10104051 0.426 T 0.404 0.447 0.555 
7512 C>T Intron 1 rs3779788 0.121 T 0.160 0.083 0.107 
8415 T>A Intron 1 rs56321069 0.183 A 0.228 0.138 0.113 
10987 C>A Intron 2  0.122 A 0.140 0.106 0.498 
11090 C>G Intron 2 rs8176337 0.190 G 0.239 0.146 0.109 
12449 G>A Intron 2  0.117 A 0.152 0.083 0.142 
12550 G>A Intron 2  0.118 A 0.156 0.083 0.128 
12810_12829 dup20 Intron 2  0.126 G 0.163 0.089 0.132 
12853_12854 Ins16 Intron 2  0.055 C 0.054 0.056 0.972 
12861_12864 del4 Intron 2  0.060 C 0.054 0.933 0.727 
13003 G>T Intron 2  0.053 T 0.053 0.052 0.973 
14114 T>C Intron 3 rs73667472 0.080 C 0.065 0.094 0.471 
15425 T>C Intron 4 rs249 0.095 C 0.085 0.104 0.654 
15449_15450 Ins2 Intron 4  0.063 C 0.096 0.031 0.068 
15653 delA Intron 4  0.410 C 0.394 0.426 0.656 
15836 C>T Intron 4 rs253 0.410 C 0.394 0.426 0.656 
16316 C>G Intron 5 rs254 0.074 G 0.060 0.913 0.487 
16320 T>C Intron 5 rs255 0.105 C 0.106 0.104 0.960 
16386 C>T Intron 5 rs256 0.118 T 0.133 0.104 0.538 
16671 G>C Intron 5 rs258 0.409 C 0.380 0.436 0.440 
17231 C>T Intron 5 rs263 0.135 T 0.148 0.122 0.618 
17599 G>A Intron 5 rs264 0.116 A 0.128 0.104 0.613 
18086 T>G Intron 6 rs269 0.119 G 0.144 0.093 0.293 
18095 C>A Intron 6 rs270 0.201 A 0.140 0.261 0.045 
18121 G>A Intron 6 rs271 0.109 A 0.130 0.087 0.343 
18395_18396 insT Intron 6  0.121 G 0.138 0.104 0.471 
18822 T>C Intron 6 rs277 0.232 C 0.181 0.281 0.101 
18942 G>A Intron 6 rs278 0.211 A 0.170 0.250 0.177 
19442 A>T Intron 6 rs281 0.242 T 0.207 0.278 0.262 
19445 C>G Intron 6 rs282 0.129 G 0.133 0.125 0.866 
19517 C>T Intron 6 rs283 0.161 T 0.167 0.156 0.847 
19608 C>T Intron 6 rs285 (PvuII) 0.407 T 0.444 0.370 0.304 
19675 A>T Intron 6 rs286 0.060 T 0.111 0.011 0.004 
19975 A>G Intron 6 rs287 0.172 G 0.244 0.104 0.011 
20038 T>C Intron 6 rs289 0.159 C 0.221 0.104 0.032 
20271 T>C Intron 6 rs291 0.163 C 0.234 0.094 0.009 
20363 A>T Intron 6  0.053 T 0.043 0.062 0.538 
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Table 10 (Continued) 
20505_20506 insA Intron 6  0.163 G 0.234 0.094 0.009 
20544 T>C Intron 6 rs294 0.080 C 0.087 0.073 0.723 
20657 A>C Intron 6 rs295 0.163 C 0.234 0.094 0.009 
20790 T>C Intron 6 rs297 0.163 C 0.234 0.094 0.009 
21353 T>C Intron 7 rs301 0.172 C 0.223 0.120 0.061 
21780 T>G Intron 7 rs304 0.103 G 0.174 0.034 0.002 
21820 A>G Intron 7 rs305 0.108 G 0.179 0.037 0.003 
22044_22047 del4 Intron 7  0.075 A 0.087 0.064 0.550 
22416 G>C Intron 7 rs312 0.072 C 0.080 0.065 0.711 
22461 G>A Intron 7 rs314 0.180 A 0.244 0.120 0.031 
22855 C>A Exon 8 rs316(T361T) 0.079 A 0.074 0.083 0.821 
23190_23191 del2 Intron 8  0.500 A 0.456 0.453 0.228 
23192 G>T Intron 8  0.068 T 0.122 0.012 0.004 
23395 A>C Intron 8 rs319 0.293 C 0.282 0.302 0.776 
23636 A>C Intron 8 rs322 0.170 C 0.227 0.117 0.048 
23747 T>C Intron 8 rs325 0.067 C 0.102 0.033 0.067 
23858 A>G Intron 8 rs326 0.206 G 0.278 0.133 0.017 
23955 T>G Intron 8 rs327 0.192 G 0.261 0.122 0.018 
23496 T>G Intron 8 rs320 (HindIII) 0.185 G 0.244 0.128 0.053 
24815 G>A Intron 9 rs330 0.111 A 0.128 0.094 0.456 
24824 G>A Intron 9 rs331 0.122 A 0.154 0.096 0.247 
24852 T>C Intron 9 rs12679834 0.080 C 0.138 0.021 0.003 
25049 G>A Intron 9  0.063 A 0.043 0.083 0.248 
25335 C>T Intron 9  0.079 T 0.138 0.021 0.003 
25352 A>C Intron 9  0.079 C 0.138 0.021 0.003 
25844 T>G Intron 9  0.074 G 0.130 0.021 0.004 
26201 T>G Intron 9  0.077 G 0.136 0.021 0.004 
26234 T>G Intron 9 rs10099160 0.282 G 0.250 0.312 0.341 
27229 C>T Intron 9 rs11570891 0.082 T 0.144 0.021 0.002 
27249 G>A Exon 10-3' UTR rs4922115 0.085 A 0.087 0.083 0.929 
28036 A>G Exon 10-3' UTR rs11570892 0.101 G 0.117 0.085 0.468 
28067 A>T Exon 10-3' UTR rs3208305 0.203 T 0.278 0.130 0.014 
28093 C>T Exon 10-3' UTR rs1803924 0.082 T 0.141 0.022 0.004 
28382 C>T Exon 10-3' UTR rs1059507 0.110 T 0.120 0.100 0.673 
28464 C>A Exon 10-3' UTR rs3735964 0.079 A 0.138 0.021 0.003 
28490 A>G Exon 10-3' UTR rs3200218 0.279 G 0.255 0.302 0.472 
28911 T>C Exon 10-3' UTR rs13702 0.200 C 0.277 0.125 0.009 
28982 T>C Exon 10-3' UTR rs1059611 0.079 C 0.138 0.021 0.003 
29046_29047 Ins2 Exon 10-3' UTR  0.079 G 0.138 0.021 0.003 
29086 C>T Exon 10-3' UTR rs15285 0.200 T 0.277 0.125 0.009 
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Table 10 (Continued) 
29088 C>A Exon 10-3' UTR rs3866471 0.105 A 0.117 0.094 0.601 
29287 G>A 3' flanking rs3916027 0.184 A 0.255 0.115 0.012 
29315 T>G 3' flanking rs9644636 0.339 G 0.348 0.330 0.795 
29487 T>A 3' flanking rs4921683 0.105 A 0.117 0.094 0.601 
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Table 11.Distribution of relatively uncommon or rare LPL variants in high and low HDL-C groups in NHWs 
LPL variant 







208 T>C 5' flanking rs1470186 0.016 0.021 0.011 
351 C>A 5' flanking  0.005 0.011 0.000 
428 G>A 5' flanking rs73667465 0.016 0.021 0.011 
549 C>T 5' flanking rs17091742 0.016 0.021 0.011 
958 G>A 5' flanking  0.005 0.000 0.011 
1088 G>T 5' flanking  0.005 0.011 0.000 
1090 T>G 5' flanking rs1800590 (-T93G) 0.011 0.011 0.010 
1130 G>C 5' flanking  0.005 0.000 0.010 
2913 T>C Intron 1  0.005 0.000 0.011 
4621 C>G Intron 1  0.021 0.021 0.021 
4948 C>G Intron 1 rs6997330 0.022 0.033 0.010 
5094 C>G Intron 1  0.005 0.000 0.011 
5107 C>T Intron 1  0.005 0.011 0.000 
5118 A>T Intron 1  0.022 0.043 0.000 
5200 C>T Intron 1  0.006 0.000 0.011 
5531 G>A Intron 1 rs1031045 0.016 0.022 0.011 
5772 A>G Intron 1 rs60633545 0.016 0.022 0.010 
6383 G>T Intron 1  0.005 0.011 0.000 
6435 G>C Intron 1  0.005 0.011 0.000 
6477 T>C Intron 1  0.005 0.011 0.000 
6553 C>T Intron 1 rs59254395 0.016 0.021 0.010 
6554 A>G Intron 1 rs56043715 0.016 0.021 0.010 
7130 T>C Intron 1 rs28615996 0.021 0.029 0.014 
7131 T>G Intron 1  0.007 0.014 0.000 
7313 G>A Intron 1 rs28645722 0.016 0.022 0.010 
7388 C>G Intron 1 rs28575919 0.016 0.021 0.010 
7503 T>C Intron 1 rs6999612 0.016 0.021 0.010 
7556 T>C Intron 1 rs59811201 0.016 0.021 0.010 
8221 A>C Intron 1 rs7000460 0.018 0.026 0.011 
8250 G>A Intron 1 rs59630933 0.019 0.026 0.012 
8467 C>T Intron 1  0.005 0.000 0.010 
8516 delG Intron 1  0.011 0.011 0.010 
9015 A>G Intron 1 rs28445964 0.021 0.022 0.020 
9024 T>C Intron 1  0.008 0.000 0.014 
9130 T>A Intron 1 rs13252357 0.005 0.011 0.000 
9411 A>C Intron 1 rs28689946 0.016 0.021 0.011 
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Table 11 (Continued) 
9418 G>A Intron 1 rs28582042 0.016 0.021 0.011 
9589 C>T Intron 1  0.016 0.021 0.011 
9696 G>T Intron 1 rs73667468 0.016 0.022 0.010 
9914 T>G Intron 1 rs73667469 0.016 0.022 0.011 
10127 G>A Exon 2 rs1801177 (D9N) 0.016 0.021 0.010 
10632 C>T Intron 2  0.005 0.000 0.001 
10912 A>G Intron 2  0.022 0.000 0.043 
11050 T>C Intron 2 rs7016529 0.016 0.023 0.010 
11228 T>C Intron 2  0.005 0.011 0.000 
11574 G>A Intron 2 rs34123038 0.049 0.056 0.043 
11600 G>C Intron 2  0.011 0.000 0.021 
11760 A>C Intron 2 rs73667470 0.016 0.021 0.010 
11888_11889 insA Intron 2  0.011 0.021 0.000 
12224_12920 del697 Intron 2  0.005 0.011 0.000 
12484 C>A Intron 2  0.048 0.044 0.052 
12878_12889 del12 Intron 2  0.005 0.011 0.000 
12884_12887 del4 Intron 2  0.016 0.033 0.000 
13639 G>A Intron 2  0.011 0.021 0.000 
13854 G>A Exon  3 rs1121923 (V108V) 0.016 0.021 0.010 
15206 C>A Intron 3 rs343 0.042 0.064 0.021 
15245 G>A Exon 4 rs248 (E118E) 0.047 0.053 0.042 
16442 G>C Intron 5  0.005 0.000 0.010 
16563 T>A Intron 5  0.016 0.011 0.021 
17476 A>C Intron 5  0.005 0.000 0.010 
17948 A>G Exon 6 rs268 (N291S) 0.033 0.022 0.043 
18065 T>G Intron 6  0.009 0.000 0.017 
18297 A>C Intron 6  0.005 0.011 0.000 
18462 T>G Intron 6  0.005 0.000 0.010 
18621 C>T Intron 6  0.005 0.011 0.000 
18708 T>C Intron 6 rs276 0.021 0.021 0.021 
19815 G>A Intron 6  0.005 0.011 0.000 
20080 C>T Intron 6  0.005 0.011 0.000 
20663 G>A Intron 6 rs296 0.005 0.000 0.010 
21125_21128 del4 Intron 6  0.005 0.000 0.011 
21895 T>G Intron 7 rs308 0.012 0.013 0.011 
21965 C>T Intron 7 rs310 0.006 0.013 0.000 
22514 T>C Intron 7 rs315 0.011 0.000 0.022 
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Table 11 (Continued) 
23388 C>G Intron 8 rs318 0.018 0.024 0.012 
23573 T>C Intron 8  0.017 0.024 0.011 
24143 C>G Exon 9 rs328 (Ser447X) 0.005 0.011 0.000 
24505 A>G Intron 9 rs329 0.016 0.021 0.011 
24573 T>C Intron 9  0.005 0.000 0.011 
24899 C>T Intron 9  0.016 0.021 0.010 
25005 A>G Intron 9  0.005 0.011 0.000 
25320 C>T Intron 9  0.005 0.011 0.000 
27000 C>T Intron 9  0.029 0.044 0.012 
27160 T>A Intron 9  0.027 0.058 0.000 
27611 T>C Exon 10-3' UTR rs3289 0.016 0.022 0.010 
27688 C>T Exon 10-3' UTR  0.005 0.000 0.010 
27783 A>T Exon 10-3' UTR  0.011 0.022 0.000 
28407 C>A Exon 10-3' UTR  0.026 0.021 0.031 
28524 C>T Exon 10-3' UTR  0.005 0.000 0.010 
29474 C>T 3' flanking  0.026 0.043 0.010 
29557_29558 InsA 3' flanking  0.005 0.000 0.010 
29716 T>C 3' flanking  0.026 0.043 0.010 
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3.3   LINKAGE DISEQUILIBRIUM (LD) AND TAGGER ANALYSES OF LPL 
VARIANTS 
We used LD and Tagger analysis to identify tagSNPs for the common variants (MAF≥ 0.05) that 
we identified by resequencing. By using tagger analysis with an r2 cutoff of 0.9, 43 tagSNP bins 
were identified. Table 12 shows the bins identified by Tagger analysis and Figure 5 demonstrates 
the LD plot. Twelve variants that were genotyped in our entire NHW sample are underlined in 
Table 12. We also used LD analysis in Haploview to see the LD pattern of the 32 common 
variants that had p-value≤0.05 when comparing the allele frequencies between the high HDL-C 
and low HDL-C groups (Figure 6). 
Table 12. Tagger results using Haploview of LPL common variants in NHWs 
Bin Variants captured 
1 28093, 23747, 26201, 25352, 25844, 25335, 24852, 29046_29047ins2, 28464, 28982 
2 29547, 29487, 24824, 24815, 28036, 28382, 29088 
3 28911, 29086, 23858, 29287, 28067 
4 7512, 12810_12829ins20, 12550, 12449, 2335 
5 16386, 18121, 17599, 18395_18396ins1 
6 20790, 20505_20506ins1, 20657, 20271 
7 16671, 15653del1, 15836 
8 23955, 23636, 23496(HindIII) 
9 26234, 23395, 28490 
10 22855, 22416, 27249 
11 20038, 19975, 21353 
12 3558, 3964 
13 16320, 16316 
14 21780, 21820 
15 8415, 11090 
16 13003, 12853_12854ins16 
17 18086, 1723 
18 6821 
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                                     Figure 5. LD analysis of identified common variants in NHWs 
Color Scheme for r2 
r2 = 0 White 
0< r2 <1 Shades of Grey 
r2 =1 Black 









Figure 6. LD analysis of the 32 identified variants which had a statistically significant p-value <0.05 when 
comparing the allele frequencies between the high HDL-C and low HDL-C groups 
Color Scheme for r2 
r2 = 0 White 
0< r2 <1 Shades of Grey 
r2 =1 Black 
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3.4    GENOTYPING OF IDENTIFIED VARIANTS IN THE ENTIRE NHW SAMPLE 
AND THEIR ASSOCIATION ANALYSIS WITH PLASMA LIPOPROTEIN LEVELS 
To date, we have genotyped 12 variants in our NHW sample (n=623) using pre-made TaqMan 
SNP Genoytping Assays. Genotyping results and features of these tagSNPs are shown in the 
Table 13.  




Location Position (Nucleotide #) 
Number of  individuals 
genotyped 








rs3779787 Intron 1 2335 619 0.175 0.153 99.40 0.376 
rs13266204 Intron 1 4424 620 0.259 0.215 99.50 0.616 
rs1534649 Intron 1 4060 618 0.472 0.453 99.20 0.599 
rs249 Intron 4 15425 614 0.075 0.074 98.60 0.211 
rs253 Intron 4 15836 623 0.450 0.451 100.00 0.505 
rs264 Intron 5 17599 605 0.142 0.140 97.10 0.428 
rs270 Intron 6 18095 618 0.208 0.172 99.20 0.896 
rs283 Intron 6 19517 618 0.188 0.201 99.20 0.352 
rs312 Intron 7 22416 617 0.092 0.112 99.00 0.976 
rs327 Intron 8 23955 619 0.250 0.264 99.40 0.478 
rs3289 Exon 10 3’UTR 27611 622 0.042 0.026 99.80 1.000 
rs1059611 Exon 10 3’UTR 28982 618 0.133 0.106 99.20 1.000 
                * CEU: U.S. residents with northern and western European 
 
None of the variants showed deviation from HWE (P>0.05) in the total sample. Figure 7 
shows the LD analysis that was repeated for the variants screened using TaqMan assays. The LD 
patterns between the 12 variants were similar to those observed in the subset (high and low HDL 
groups) of our sample that we used for sequencing.  
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           Figure 7. LD analysis of the variants screened in the entire NHW sample 
 
These 12 variants screened in total NWH sample were analyzed by using both additive 
and dominant models for their relation to plasma total cholesterol, HDL-C, LDL-C and TG levels. 
Table 14 shows the genotype counts, covariate adjusted mean for each lipid level and adjusted p-
values for additive and dominant models, respectively. The remaining common tagSNPs that are 
not included in these analyzes are currently being genotyped by Sequenome IPLEX genotyping 
platform so they are not included in this study.  
Of the 12 variants, 4 (rs1059611, rs270, rs3779787, rs327) had statistically significant p-
values associated with HDL-C level in both additive and dominant models, but rs13266204 had a 
significant P-value (0.013) only in additive model and had a marginally significant p-value 
(0.080) in the dominant model. 
Two of the 12 variants (rs327, rs270) showed statistically significant association with 
triglycerides levels in both additive and dominant models. rs312 showed statistically significant 
Color Scheme for r2 
r2 = 0 White 
0< r2 <1 Shades of Grey 
r2 =1 Black 
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association with triglyceride levels in additive model (P=0.0091) and  it showed marginally 
significant association in the dominant (P=0.050) model. On the other hand, rs283 had a 
statistically significant P-value (0.024) associated with TG levels only in dominant model but it 
had a marginally significant P-value (0.068) in additive model.  
There were two variants (rs270 and rs312) that had marginally statistically significant P-
values associated with LDL-C levels; rs270 showed marginally significant association in only 
additive model (P=0.056), however, rs312 showed marginally significant association in only 
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Table 14.Genotype distributions and adjusted p-values for 12 LPL variants in NHWs 
 rs13266204_Add rs13266204_Dom 
 
Total Cholesterol Adjusted mean± 
SD 
P-value 
AA[380]           GA[203]                      GG[31] 
216.03±2.13    219.34±2.90        218.32±7.21 
P= 0.400 
AA[380]                             GA/GG[234] 
216.02±2.13                        219.2±2.69 
P=0.342 
 
HDL-C Adjusted mean± SD 
P-value 
AA[383]                GA[203]                 GG[31] 
50.95±0.64           49.95±0.88       45.26±2.19 
P=0.013 
AA[383]                               GA/GG[234] 
50.93±0.65                            49.3±0.82 
P=0.080 
 
LDL-C Adjusted mean± SD 
P-value 
AA[378]                GA[203]                 GG[29] 
137.40±1.97        141.56±2.68     143.13±6.89 
P=0.164 
AA[378]                               GA/GG[232] 
137.41±1.97                         141.76±2.50 
P=0.160  
 
Triglycerides Adjusted mean± SD 
P-value 
AA[380]            GA[203]                     GG[31] 
140.70±3.52     139.13±4.79       180.90±11.92 
P=0.082 
AA[380]                               GA/GG[234] 
140.9±3.54                           144.89±4.49 
P=0.329 
 rs312_Add rs312_Dom 
 
Total Cholesterol Adjusted mean± 
SD 
P-value 
GG[482             GC[122]                        CC[7] 
215.70±1.8      222.44±3.67       211.87±1.15 
P=0.174 
GG[482]                                  GC/CC[129] 
215.71±1.89                             221.89±3.57 
P=0.118 
 
HDL-C Adjusted mean± SD 
P-value 
GG[484]            GC[123]                      CC[7] 
50.21±0.58       51.06±1.12             57.26±4.66 
P=0.118 
GG[482]                                    GC/CC[129] 
50.21±0.58                               51.39±1.1 
P=0.201 
 
LDL-C Adjusted mean± SD 
P-value 
GG[480]                GC[120]                   CC[7] 
137.47±1.75     144.04±3.42     138.97±13.99 
P=0.114 
GG[480]                                   GC/CC[127] 
137.47±1.75                              143.77±3.33 
P=0.087 
 
Triglycerides Adjusted mean± SD 
P-value 
GG[482]                 GC[122]                   CC[7] 
144.13±3.1     136.49±6.14 82      85.52±25.36 
P=0.009 
GG[482]                                   GC/CC[129] 
144.19±3.16                             133.65±6.00 
P=0.050 
 rs1059611_Add rs1059611_Dom 
 
Total Cholesterol Adjusted mean± 
SD 
P-value 
TT[490]                  TC[116]                     CC[7] 
216.74±1.8        219.38±3.73         210.19±15.10 
P=0.713 
TT[490]                                    TC/CC[123] 
216.76±1.89                             218.88±3.63 
P=0.599 
 
HDL-C Adjusted mean± SD 
P-value 
TT[491]                   TC[117]                  CC[7] 
49.71±0.58           52.78±1.13           49.36±4.61 
P=0.036 
TT[491]                                   TC/CC[124] 
49.72±0.58                                   52.6±1.1 
P=0.018 
 
LDL-C Adjusted mean± SD 
P-value 
TT[486]                  TC[117]                   CC[7] 
139.10±1.75        138.78±3.45      138.41±13.96 
P=0.925 
TT[486]                                   TC/CC[123] 
139.10±1.75                             138.76±3.36 
P=0.928 
 
Triglycerides Adjusted mean± SD 
P-value 
TT[490]                  TC[115]                   CC[7] 
143.66±3.117      139.91±6.29      113.17±25.35 
P=0.346 
TT[490]                                   TC/CC[122] 
143.72±3.17                             138.44±6.13 
P=0.481 
                  Mean and p-values adjusted for BMI, age, smoking, and sex 
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 rs253_Add rs253_Dom 
 
Total Cholesterol Adjusted mean± SD 
P-value 
CC[181]               TC[315]               TT[121] 
213.91±3.01       218.61±2.32       218.93±3.71 
P=0.231 
CC[181]                                TC/TT[436] 
213.82±3                               218.69±2 
 P=0.168 
 
HDL-C Adjusted mean± SD 
P-value 
CC[182]              TC[316]                TT[122] 
51.19±0.92         49.94±0.71           50.38±1.13   
P=0.595 
CC[182]                               TC/TT[438] 
51.19±0.92                             50.06±0.61 
P=-0.290 
 
LDL-C Adjusted mean± SD 
P-value 
CC[181]                  TC[312]             TT[120] 
136.34±2.78     140.15±2.16         140.34±3.45  
 P=0.309 
CC[181]                               TC/TT[432] 
136.34±2.78                       140.20±1.86 
P=0.239 
              
Triglycerides Adjusted mean± SD 
 P-value 
CC[182]              TC[314]                TT[121] 
139.61±5.01         143.13±3.87       143.24±6.20   
P=0.686 
CC[182]                                 TC/TT[435] 
139.61±5.00                        143.16±3.35 
P=0.683 
 rs1534649_Add rs1534649_Dom 
 
Total Cholesterol Adjusted mean± SD 
P-value 
GG[177]              GT[314]              TT [122] 
216.50±3.022     217.63±2.32       215.99±3.65 
P=0.956 
GG[177]                              GT/TT [436] 
216.51±3.02                        217.17±2  
P=0.850 
 
HDL-C Adjusted mean± SD 
P-value 
GG[179]              GT[314]              TT [123] 
50.47±0/92          50.52±0.71       49.82±1.12    
P=0.730 
GG[179]                                GT/TT [437] 
50.48±0.92                            50.32±0.61  
P=0.815  
 
LDL-C Adjusted mean± SD 
P-value 
GG[177]           GT[311]                 TT [121] 
138.43              138.81±2.16           139.61±3.39 
P=0.792 
GG[177]                               GT/TT [432] 
138.43±2.78                          140.20±1.86 
P=0.855 
 
Triglycerides Adjusted mean± SD 
P-value 
GG[179]               GT[312]              TT [122] 
145.73±5.04    140.98±3.91            138.33±6.13 
P=0.175 
GG[179]                               GT/TT [434] 
145.74±5.04                         140.24±3.36    
P=0.219 
 rs327_Add rs327_Dom 
 
Total Cholesterol Adjusted mean± SD 
P-value 
TT[337]              TG[229]                GG[47] 
217.07±2.23       216.02±2.68         222.89±5.84 
P=0.645 
TT[337]                              TG/GG[276]           
217.07±2.23                        217.18±2.47 
P=0.971 
 
HDL-C Adjusted mean± SD 
P-value 
TT[338]             TG[231]                 GG[47] 
49.64±0.68       50.97±0.82             52.52±1.80   
P=0.030    
TT[338]                              TG/GG[278]           
49.64±0.68                           51.23±0.76 
P=0.038 
LDL-C Adjusted mean± SD 
P-value 
TT[335]           TG[227]                   GG[47] 
139.14±2.07    137.65±2.50            144.17±5.40 
P=0.746 
TT[335]                            TG/GG[274]           
139.14±2.07                       138.76±2.29 
P=0.900 
 
Triglycerides Adjusted mean± SD 
P-value 
TT[337]             TG[229]                  GG[47] 
146.94±3.71      136.95±4.48           132.08±9.72   
P=0.014 
TT[337]                              TG/GG[276]         
146.94±3.70                       136.12±4.10    
P=0.015  
                  Mean and p-values adjusted for BMI, age, smoking, and sex 
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 rs264_Add rs264_Dom 
 
Total Cholesterol Adjusted mean± SD 
P-value 
GG[440]                GA[150]                 AA[9] 
216.77±1.96        217.53±3.31          222.74±13.31 
P=0.709 
GG[440]                                    GA/AA[159] 
216.76±1.96                              217.81±3.22 
P=0.774 
 
HDL-C Adjusted mean± SD 
P-value 
GG[442]                  GA[151]              AA[9] 
50.20±0.60              51.03±1.02         50.24±4.12 
P=0.380 
GA[442]                                   GA/AA[160] 
50.2±0.6                                     50.99±0.99 
P=0.370 
 
LDL-C Adjusted mean± SD 
P-value 
GG[438]                 GA[148]               AA[9] 
138.77±1.82           138.18±3.08       147.98±12.31 
P=0.850 
G[438]                                       GA/AA[157] 
138.75±1.82                               138.72±3.00 
P=0.993 
 
Triglycerides Adjusted mean± SD 
P-value 
GG[442]                  GA[148]               AA[9] 
143.18±3.30        141.75±5.62         124.00±22.50 
P=0.660 
G[442]                                       GA/AA[157] 
143.21±3.30                              140.77±5.47 
P=0.783 
 rs270_Add rs270_Dom 
 
Total Cholesterol Adjusted mean± SD 
P-value 
CC[419]                   CA[174]             AA[19] 
215.90±2.02        219.26±3.04          231.19±9.08 
P=0.100 
CC[419]                                    CA/AA[193] 
215.91±2.02                              220.45±2.89 
P=0.187 
 
HDL-C Adjusted mean± SD 
P-value 
CC[422]                     CA[174]             AA[19] 
51.22±0.62               48.58±0.94       49.91±2.80 
P=0.020 
CC[422]                                    CA/AA[193] 
51.23±0.62                                  48.71±0.89 
P=0.008 
 
LDL-C Adjusted mean± SD 
P-value 
CC[417]                     CA[172]                AA[19] 
137.53±1.87              141.17±2.83       153.95±8.49 
P=0.056 
CC[417]                                    CA/AA[191] 
137.54±1.87                               142.26±2.69 
P=0.123 
 
Triglycerides Adjusted mean± SD 
 P-value 
CC[419]                   CA[174]                 AA[19] 
137.93±3.39           153.27±5.13       136.79±15.31 
P=0.031 
CC[419]                                    CA/AA[193] 
137.93±3.39                               151.62±4.87 
P=0.012 
 rs249_Add rs249_Dom 
 
Total Cholesterol Adjusted mean± SD 
P-value 
TT[523]               TC[79]                    CC[6] 
217.39±1.83      214.25±4.55         247.51±16..36 
P=0.745 
TT[523]                                       TC/CC[85] 
217.34±1.83                               216.54±4.41 
P=0.864 
 
HDL-C Adjusted mean± SD 
P-value 
TT[526]               TC[79]                     CC[6] 
50.62±0.56       49.41±1.39             46.93±5.00 
P=0.343 
TT[526]                                        TC/CC[85] 
50.63±0.45                                   49.24±1.34 
P=0.355 
 
LDL-C Adjusted mean± SD 
P-value 
TT[521]                  TC[77]                  CC[6] 
139.39±1.70        134.85±4.26          170.56±15.15 
P=0.890 
TT[521]                                        TC/CC[83] 
139.34±1.70                               137.36±4.13 
P=0.653 
 
Triglycerides Adjusted mean± SD 
P-value 
TT[524]                 TC[78]                   CC[6] 
140.82±3.03     147.94±7.61            149.88±27.24 
P=0.380 
TT[524]                                        TC/CC[84] 
140.82±3.03                               148.08±7.35 
P=0.4213 
                   Mean and p-values adjusted for BMI, age, smoking, and sex 
                   Natural log transformed data were used for association analysis of triglycerides and HDL-C levels 
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 rs283_Add rs283_Dom 
 
Total Cholesterol Adjusted mean± SD 
P-value 
AA[394]               AT[189]                    TT[29] 
217.60±2.10        216.97±2.99           214.60±7.52 
P=0.717 
AA[394]                                AT/TT[218] 
217.59±2.1                             216.66±2.79 
P=0.782 
 
HDL-C Adjusted mean± SD 
P-value 
AA[397]                      AT[189]               TT[29] 
50.68±0.64               50.09±0.91          48.17±2.29 
P=0.350 
AA[397]                               AT/TT[218] 
50.68±064                             49.83±0.85 
P=0.402 
 
LDL-C Adjusted mean± SD 
P-value 
AA[392]                  AT[187]               TT[29] 
139.80±1.95         137.57±2.78           138.53±6.96 
P=0.560 
AA[392]                               AT/TT[216] 
139.80±1.95                         137.70±2.59 
P=0.504 
            
Triglycerides Adjusted mean± SD 
 P-value 
AA[394]                   AT[189]                 TT[29] 
138.20±3.48         151.36±4.96         138.14±12.49 
P=0.068 
AA[394]                               AT/TT[218] 
138.17±3.48                          149.59±4.63 
P=0.024 
 rs3289_Add rs3289_Dom 
 
Total Cholesterol Adjusted mean± SD 
P-value 
TT[584]                    TC[32]                   CC[0] 
217.66±1.75           209.97±7.09 
 P=0.289           
TT[584]                               TC/CC[32]                                                  
217.66±1.75                       209.97±7.09 
P=0.289 
 
HDL-C Adjusted mean± SD 
P-value 
TT[587]                     TC[32]                 CC[0] 
50.44±0.53            50.42±2.17 
P=0.876 
TT[587]                               TC/CC[32] 
50.44±0.53                           50.42±2.17 
P=0.876 
 
LDL-C Adjusted mean± SD 
P-value 
TT[580]                     TC[32]                 CC[0] 
139.62±1.62          129.13±6.55   
P=0.118 
TT[580]                               TC/CC[32] 
139.62±1.62                       129.13±6.55 
P=0.118 
 
Triglycerides Adjusted mean± SD 
P-value 
TT[584]                     TC[32]                   CC[0] 
141.28±2.91            152.51±11.81 
P=0.378 
TT[584]                               TC/CC[32] 
141/28±2.91                      152.51±11.81 
P=0.378  
 rs3779787_Add rs3779787_Dom 
 
Total Cholesterol Adjusted mean± SD 
P-value 
GG[436]                 GT[166]                   TT[11] 
217.06±1.98          216.70±3.19            234±12.15 
  P=0.582 
GG[436]                            GT/TT[177] 
217.04±1.98                       217.74±3.1 
P=0.844 
 
HDL-C Adjusted mean± SD 
P-value 
GG[436]                   GT[167]              TT[11] 
49.73±0.60              52.06±0.97         48.94±3.69 
P=0.033 
GG[438]                            GT/TT[178] 
49.74±0.6                           51.88±0.94 
P=0.018 
 
LDL-C Adjusted mean± SD 
P-value 
GG[433]                   GT[165]                 TT[11] 
139.35 ±1.84           136.99±2.95        159.09±11.22 
P=0.830 
GG[433]                            GT/TT[176] 
139.31±1.84                       138.33±2.88 
P=0.770 
              
Triglycerides Adjusted mean± SD 
P-value 
GG[438]                   GT[164]            TT[11] 
144.66±3.29          137.02±5.33          129.24±20.22 
P=0.225 
GG[438]                             GT/TT[175] 
144.68±3.28                       136.55±5.18 
P=0.222  
                   Mean and p-values adjusted for BMI, age, smoking, and sex 
                   Natural log transformed data were used for association analysis of triglycerides and HDL-C levels 
  64 
4.0   DISCUSSION 
Lipoprotein lipase (LPL) is a biological candidate gene for cardiovascular disease due to its major 
role in the catabolism of TG rich lipoproteins. Clinically abnormal lipid levels have been 
associated with CHD, atherosclerosis and obesity in individuals who have functional DNA 
sequence variation in their LPL gene (Murthy et al. 1996; Reymer et al. 1995; Brunzell et al. 
1995; Wiebusch et al. 1992). The sequence variation of LPL is also associated with Mendelian 
disorders. LPL deficiency, known as  Type 1 hyperlipoproteinemia or familial chylomicronemia 
(MIM 238600), is a rare autosomal recessive disorder (1/1,000,000) caused by defects in the LPL 
gene and it is correlated with severe hypertriglyceridemia due to chylomicronemia and VLDL 
accumulation with very low levels of LDL-C and HDL-C levels (<20mg/dL).  
Several candidate gene studies and genome wide association studies (GWAS) have 
identified many SNPs in the LPL gene associated with lipid levels (Aulchenko et al. 2009; 
Kooner et al. 2008; Klos et al. 2006; Chasman et al. 2008; Ahn et al. 1993; Razzaghi et al. 2000; 
Willer et al. 2008; Chamberlein et al. 1999; Wallacee et al. 2008; Humphries et al. 1998). In this 
study, we resequenced the entire LPL gene (~30kb) in 95 healthy NHW individuals having 
extreme HDL-C to evaluate the impact of LPL genetic variation on HDL-C and correlated lipid 
levels. Our comprehensive resequencing effort of this gene, the first to our knowledge, revealed a 
total of 179 variants; 162 single nucleotide substitutions, 17 indels and a microsatellite 
(tetranucleotide repeat marker).  Of 178 variants, 88 had a MAF≥0.05 and 91 had a MAF <0.05.  
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4.1 COMPARISON OF OUR RESEQUENCING RESULTS WITH TWO PUBLISHED 
STUDIES 
We compared our sequencing results with two previous published sequencing reports (Nickerson 
et al. 1998; Wright et al. 2008). Nickerson et al. (1998) examined a portion of the LPL gene 
(9.7kb), from 3’ end of intron 3 to 5’ end of intron 9, among 71 individuals from three racial 
groups including European-Americans from Rochester, Minnesota (n=23), African-Americans 
from Jackson, Mississippi (n=24) and Europeans from North Karelia, Finland (n=24). They 
identified 88 variants, of which 79 were single nucleotide substitutions, 8 were indels and one was 
a microsatellite. Of 88 variant, 56 and 59 were identified in their white populations, North 
Karelia, Finland and Rochester, Minnesota, respectively. We compared our sequencing results 
with the variants they identified in Rochester samples. Fifty three of the 59 reported variants were 
founded in our NHW sample in this 9.7 kb region, including the reported microsatellite (ATTT)n. 
Of the 6 reported variants, which we did not find in this study, 5 had MAF ≤0.05  and one was 
8538delA with a MAF of 0.20 which was observed as a sequencing artifact in our sample. On the 
other hand, we identified 17 variants (0.005≤MAF≤0.053) that were not reported in their study.  
This inconsistency might be due to the sample size differences or due to the different software 
that were used in identifying variants (Nickerson et al. used PolyPhred Program, but we used 
Variant Reporter and Sequencher). 
Wright et al. (2008) sequenced the 10 exons and intron-exon boundaries of the LPL gene, 
plus 1kb in the promoter region, and about 300 bases in the 3’flanking region in 19 Northern Irish 
individuals with extreme hypertriglyceridemia (HTG). They identified a total of 42 variants and 
found rs268 (N291S) to be a major predisposing factor for HTG. We identified 39 of the reported 
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42 variants, including N291S (discussed later on). The three variants they identified (590G>A, 
1018G>A and 345A>C) but we did not, had MAF <0.05 in their Northern Irish sample. Two of 
these 3 variants were exonic (590(G>A) in exon 5 and 1018G>A in exon 6). Interestingly, these 
two variants were not identified by Nickerson et al. (1998), either. Since Wright et al. (2008) used 
a selected sample with HTG, it is not surprising that these variants were not identified in ours and 
Nickerson et al.’s population-based samples. On the other hand, although we identified 23 exonic 
variants in our sample, they identified only 15 exonic variants including the 2 we did not identify. 
Of 11 exonic variants that they did not identify, ten were located in the UTR of exon 10, and one 
was [rs328 (Ser447X)] located in exon 9. 
4.2   DISTRIBUTION OF LPL VARIANTS AMONG HIGH AND LOW HDL-C GROUPS 
4.2.1   Distribution of common LPL variants among high and low HDL-C groups in NHWs 
Of the 88 common variants (MAF ≥0.05) observed in this study 32 showed significantly different 
distribution (P ≤0.05) between high and low HDL-C groups. Of these 32 variants, 25 have been 
previously reported in Chip Bioinformatics, and remaining 7 are the new variants. 
 Two of the common variants, rs326 (23858) and rs13702 (28911), that revealed  
significant difference between the high and low HDL-C groups in our study, have also been 
reported previously to be associated with HDL-C levels (Klos et al. 2006; Kooner et al. 2008). 
Klos et al. (2006) genotyped 3,993 individuals (1,132 black females, 807 black males, 1,101 
white females and 953 white males) for rs326 and rs13702 variants and found significant 
association with HDL-C in black males (P=0.013) and black females (P=0.004). The association 
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between HDL-C levels and rs326 was also confirmed in a GWAS (P=1.4×10-7) comprising 5,968 
individuals (Kooner et al. 2008). In both studies, the rs326/G allele was found to be associated 
with high HDL-C levels than the other allele. Likewise, in our study the frequency of the G allele 
for rs326 was higher in the high HDL-C group than the low HDL-group (0.278 vs. 0.133; 
P=0.017). As reported previously, the rs326 and rs13702 variants were in strong LD in our 
sample (r2=0.933). Our tagger analysis showed that rs13702 and rs326 were in the same bin along 
with rs15285 (29086C>T) and rs3916027 (29287G>A), which also demonstrated significant 
difference between the high and low HDL-C groups (P=0.009 and P=0.012, respectively).  
A common LPL variant in intron 8, HindIII (23496T>G, rs320), has been reported to be 
associated with plasma TG and HDL-C in several, but not all studies (Ahn et al. 1993; Razzaghi 
et al. 2000; Chamberlain et al. 1989) As expected, the frequency  of the HindIII/G allele in the 
high HDL-C group was almost twice to that observed in the low HDL-C group (0.244 vs 0.128; 
P=0.053) in our sequencing sample, The HindIII/G allele is in strong  LD with the 447X allele of 
the functional Ser447X polymorphism (rs328) in exon 9 (Razzaghi et al. 2000; Humphries et al. 
1998;). The S447X variant, which has been reported as a gain-of-function mutation, leads to a 
premature stop codon, resulting a truncated protein which is two amino acid shorter than the full-
length product that increases LPL protein expression without changing specific activity (Merkel 
et al. 2002; Rip et al. 2006). Wittrup et al. (1999) found that the carriers of Ser447X had reduced 
TGs, increased HDL-C and 0.8-fold reduced risk of ischemic heart disease. Since these two 
variants are in strong LD, there has been a debate in the literature whether HindIII is a genetic 
marker for the functional Ser447X variant or this is functional by itself (Razzaghi et al. 2000; 
Humphries et al. 1998; Merkel et al. 2002). However, Chen et al (2008) have recently 
demonstrated that the HindIII site binds to a transcription factor and affects LPL expression and 
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thus, this is a functional variant by itself. Although we identified the HindIII polymorphism in our 
sample, we found only one example of S447X (24143C>G) in the high HDL group using Variant 
Reporter. We further looked for this variant in Sequencher. However, we did not see any clear 
peaks as an evidence of variation at this site in Sequencher. 
Another common variant PvuII (rs285) that we identified in our sequencing sample has 
been previously reported to be associated with TG levels and hypertriglyceridemia in some but 
not all studies (Chamberlein et al. 1999; Ahn et al. 1993). However, in our sequencing sample we 
found a comparable frequency of the T allele between the high and low HDL-C groups (0.444 vs 
0.370; P =0.304). 
To our knowledge, seven GWA studies have found significant association signals within 
the LPL gene and flanking regions associated with HDL-C levels (Boes et al. 2010). The reported 
SNPs with the lowest p-values are: rs2083637 (P=5.5×10-18) (Aulchenko et al. 2009), rs10503669 
(P =4.1×10-19) (Willer et al. 2008), rs331 (P=9.1×10-7) (Chasman et al. 2008), rs328 (P =9×10-23) 
(Kathiresan et al. 2008b), rs17482753 (P =2.71×10-5) (Heid et al. 2008), rs17411031 (P =1.28×10-
10) (Wallacee et al. 2008), and rs326 (P =1.4×10-7) (Kooner et al. 2008). Of these 7 SNPs, we 
identified rs326 and rs331 SNPs in our study. As mentioned above, our result for rs326 was 
consistent with reported GWAS, but we did not find a significant difference between high and 
low HDL-C groups for rs331 (0.154 vs. 0.096; P =0.247), although the frequency of the A allele 
was higher in high HDL-C group which is consistent with the previous reports. The other 5 
GWAS significant SNPs are located in the distant 5’flanking region of the LPL that was outside 
the region we sequenced. 
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4.2.2   Distribution of relatively uncommon or rare LPL variants among high and low HDL-
C groups in NHWs 
In addition to the 88 common variants identified in sequencing, we identified 91 uncommon or 
rare variants (MAF< 0.05). Of the 91 relatively uncommon or rare variants, 21 were present only 
in the low HDL-C group and 25 were present only in the high HDL-C group; 45 exist in both 
groups. Since the P-values for the uncommon or rare variants (MAF< 0.05) between the two HDL 
groups were unreliable due to the small resequencing sample size (47 in high HDL and 48 in low 
HDL), we performed a preliminary analysis for 91 variants to determine the accumulation of rare 
variants in the high and low HDL-C group. Forty one of 47 (87.2%) individuals with high HDL-C 
had minimum one rare variant versus 35 of 48 (72.91%) individuals with low HDL-C; 24 of 47 
(51.1%) individuals high HDL-C had minimum two rare variants versus 16 of 48 (33.3%) 
individuals with low HDL-C; 18 of 47 (38.2%) individuals with high HDL-C had minimum three 
rare variants versus 8 out of 48 (16.6%) individuals with low HDL-C. Overall, the prevalence of 
uncommon or rare variants was higher in the high HDL-C group than the low HDL-C group, 
which contradicts observation made by Cohen et al. (2004) by sequencing three other lipid genes. 
Cohen et al (2004) resequenced the ABCA1, APOA1 and LCAT genes in individuals having 
extremely low (5th percentile) and high (95th percentile) HDL-C levels from a population-based 
sample to test whether the accumulation of rare variants collectively contribute to variation in 
HDL-C levels. They observed accumulation of rare sequence variants in subjects with low HDL-
C levels and concluded that multiple rare variants were significant contributor to low HDL-C 
levels. 
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To date, in Online Mendelian Inheritance in Man database (OMIM), 
(http://www.ncbi.nlm.nih.gov/omim) a list of 41 causative mutations or rare variants have been 
reported in LPL; 35 mutations were reported causing LPL deficiency; 4 were reported causing 
Combined familial hyperlipidemia (CFH); one single nucleotide polymorphism (SNP) (Ser447X) 
reported as contributing a defect in lipid interface recognition in a Type 1 hyperlipidemia patient 
and another SNP (rs326), a HDL-C level quantitative trait locus 11 (HDLCQ11) was reported for 
being associated with high HDL-C levels. Not surprisingly, we did not identify any example of 
the reported 35 rare mutation associated with LPL deficiency because our sample was population-
based from apparently healthy individuals. However, of the 4 reported variants associated with 
CFH, three were identified in our resequencing sample; D9N (rs1801177), -T93G (rs1800590) 
and N291S (rs268). Both coding variants, D9N and N291S, are associated with reduced 
enzymatic activty. –T93G is a functional promoter variant located in the 5’ flanking region of the 
LPL gene and is in LD with D9N among Caucasians (Zhang et al. 1996; Mailly et al. 1995; 
Merkel et al. 2002). The minor allele frequency of these variants in our resequencing sample was 
≤0.05 (Table 15) and so there were not enough individuals in the high and low HDL groups to 
make a conclusive statement about their role in affecting HDL-C levels. However, these variants 
will be genotyped in our entire sample in addition to other rare variants that we identified in the 
current study to evaluate their association with lipid levels. 
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Table 15. Distribution of identified functional variants in high and low HDL-C groups 
Nucleotide   # Alleles Location refSNP ID All MAF (n=95) 
MAF(%) assoc. allele 
High HDL-C 
MAF(%)  assoc.allele 
     Low HDL-C 
1090 T>G 5' flanking rs1800590 (-T93G) 0.011 0.011 0.010 
10127 G>A Exon 2 rs1801177 (D9N) 0.016 0.021 0.010 
17948 A>G Exon 6 rs268 (N291S) 0.033 0.022 0.043 
24143 C>G Exon 9 rs328(Ser447X)  0.005 0.011 0.000 
 
 
4.3   DISTRIBUTION OF SELECTED COMMON VARIANTS IN THE TOTAL NHW 
SAMPLE 
To date, we have screened a total of 12 common variants in the entire NHW sample (n=623) by 
using TaqMan Genotyping assays (Table 6 and Table 7 in Section 2.3). Of the 12 variants, 
rs1059611, rs270, rs3779787 and rs327 showed statistically significant association with HDL-C 
level (P<0.05) in both additive and dominant models, but rs13266204 had a significant P-value 
(0.013) only in the additive model, but showed a marginally significant association (P=0.080) in 
the dominant model. To our knowledge, none of these SNPs were previously reported as being 
significantly associated with HDL-C levels. In our resequencing samples (n=95), we also 
observed significantly different distribution of rs1059611 (28982T>C), rs270 (18095C>A), rs327 
(23955T>G) and rs13266204 (4424A>G) between the high and low HDL-C groups (P=0.003, 
0.045, 0.018, and 0.038, respectively). Although we observed significant association of 
rs3779787 in the total sample (P additive model=0.033 and P dominant model=0.018) the difference of 
minor allele frequencies between the high and low HDL-C groups was marginally significant 
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(P=0.096). This can be explained by the sample size differences in genotyping and resequencing. 
For rs3779787, T allele was associated with high HDL-C levels in our genotyping results (P additive 
model=0.033 and P dominant model=0.018) and T allele frequency was also higher in high HDL-C group 
than low HDL-C group, although it did not achieve statistical significance at 5% level (P=0.096). 
Noteworthy, although we identify only one example of the Ser447X variant in our resequencing 
sample, it was in LD with rs1059611 which was genotyped in our entire NHW sample and 
showed significant association with HDL-C levels, as discussed above. 
Two of the 12 variants, rs327 (T>G), rs270 (C>A), showed statistically significant 
association with TGs levels in both additive (P=0.014 and P=0.031, respectively) and dominant 
models (P=0.015 and P=0.012, respectively). rs312 (G>C) also showed statistically significant 
association with TG levels in additive model (P=0.009), but it showed marginally significant 
association in dominant model (P=0.050).The rs327/T and rs270/A alleles were associated with 
high TG levels as compared to other corresponding alleles of these two SNPs. Both of these 
variants have also demonstrated significant differences between the high and low HDL-C groups 
in the subset sequencing sample, as discussed above. Recently, the association between TG levels 
and rs327 was also reported by Smith et al. (2010), but they did not observe significant 
association between rs270 and TG levels in any of the statistical models that they used. In their 
study, rs327 was shown to affect regulation of LPL in vitro and they reported this as a new 
potential functional variant of LPL (Smith et al. 2010). We also observed association of rs283 
with TG levels (P=0.024); however this association was not identified by Smith et al. (2010). 
There was one variant, rs270 (C>A), that showed statistically significant association 
(P=0.020) with LDL-C levels; rs270/A allele was associated with high LDL-C levels. The same 
allele was also associated with low HDL-C (P=0.020 and 0.008, for additive and dominant 
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models, respectively) and high TG levels (P=0.031 and 0.012 for additive and dominant models, 
respectively). Additionally, rs312 (G>C) showed marginally significant association with TG 
levels in only dominant model (P=0.087); the G allele was associated with low LDL-C levels for 
this variant. 
Previously, rs3289 located in UTR of exon 10, has shown to affect LPL regulation in vitro 
and also revealed significant association with TG levels (Smith et al. 2010). However, in our 
study we found no such association with TG or other lipid traits. This might be due to different 
sample sizes and sample selection criteria that were used in genotyping. 
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5.0   CONCLUSIONS 
LPL plays a vital role in lipid metabolism and genetic variation in this gene affects monogenic 
lipid traits and also HDL-C and TG variation in the general population. To further investigate the 
role of the rare and common variation in the LPL gene, we resequenced the entire gene in selected 
individuals falling in the upper and lower 5th percentile of HDL-C in a NHW sample. We 
identified 179 variants, of which 88 had MAF≥0.05 and 91 had MAF<0.05. Of the 88 common 
variants, 32 demonstrated significant association with HDL-C levels. Overall, the prevalence of 
uncommon or rare variants was higher in the high HDL-C group than the low HDL-C group. Our 
comprehensive resequencing study reconfirms the functional significance of the LPL gene in lipid 
metabolism. 
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